{ "$schema_version": "5.3", "review_mode": "fresh", "claim_restatement": { "index_wording": "Misfolded α-synuclein is directly neurotoxic to dopaminergic neurons, and its accumulation causes the neuronal loss of Parkinson's disease.", "entry_form": "conjunction", "gradeable_restatement": "Misfolded α-synuclein is directly neurotoxic to dopaminergic neurons, and its accumulation causes the neuronal loss of Parkinson's disease.", "restatement_required": false, "split_into": [], "parent_claim": null, "scope_qualifiers": [] }, "hypothesis": { "name": "α-Synuclein neurotoxicity and Parkinson disease neuronal loss", "central_claim": "Misfolded α-synuclein is directly neurotoxic to dopaminergic neurons, and its accumulation causes the neuronal loss of Parkinson's disease.", "proposed_mechanism": "Identified misfolded α-synuclein conformers accumulate and directly injure dopaminergic neurons through cellular dependencies, accounting for neuronal loss in human Parkinson disease.", "claimed_scope": "disease-class", "claimed_level": [ "initiation", "progression" ], "is_conjunctive": true, "conjunctive_note": "Direct conformer toxicity and its causal explanation of neuronal loss in human PD are separate premises. The user does not require extracellular spread, uniform necessity/sufficiency or primary-driver status." }, "rubric_routing": { "primary_rubric": "01-neurodegeneration.md", "secondary_rubrics": [], "index_notes_applied": [ "Scope-matched aggregation retained from the index; SC4 carries the broad human sporadic PD causal claim.", "Preregistered departure from the stronger index formulation: necessity, sufficiency, primary-driver and obligatory extracellular-spread premises are not silently added.", "SNCA human genetic biology, specific conformer toxicity, in-vivo intervention and sporadic generalization adjudicated separately." ], "rubric_fit_note": "" }, "subclaim_matrix": { "subclaims": [ { "id": "SC1", "statement": "Endogenous changes in SNCA dosage or sequence cause a dopaminergic degenerative disease phenotype through α-synuclein biology.", "subclaim_type": "mechanism", "scope": "Human familial SNCA-linked dopaminergic degenerative disease; established coding variants and dosage gains considered individually.", "claimed_scope": "Human familial SNCA-linked dopaminergic degenerative disease; established coding variants and dosage gains considered individually.", "governing_rubric": "01-neurodegeneration.md", "key_evidence_anchor": "Independent endogenous SNCA coding/multiplication natural experiments with phenotype and molecular corroboration; gene-level causality does not identify a toxic conformer.", "hsef_level": "Ζ", "confidence": "High", "governing_cap_or_threshold": "Ζ convergence at familial gene-level scope", "rationale": "Human coding-change and wild-type dosage natural experiments converge with distinct causal assignment errors; verified families establish gene-level causality, not universal carrier penetrance or misfolding mediation." }, { "id": "SC2", "statement": "Identified misfolded α-synuclein species directly injure dopaminergic neurons, distinguishable from altered normal function, mere marking and exclusively indirect glial toxicity.", "subclaim_type": "mechanism", "scope": "Disease-relevant dopaminergic neuronal systems, with patient-derived, endogenous animal and artificial exposure scopes explicitly distinguished.", "claimed_scope": "Disease-relevant dopaminergic neuronal systems, with patient-derived, endogenous animal and artificial exposure scopes explicitly distinguished.", "governing_rubric": "01-neurodegeneration.md", "key_evidence_anchor": "Species-selective depletion/neutralization and matched reinstatement at relevant exposure, with dopamine-neuron survival and physiological-function controls.", "hsef_level": "Γ", "confidence": "Moderate", "governing_cap_or_threshold": "Γ system/scope and mediator-attribution boundary", "rationale": "Conformer manipulations and patient-derived/isogenic neuronal assays demonstrate direct injury capability; ectopic variants, amplified seeds and culture/model scopes do not yet isolate endogenous toxic-species dependence in human disease." }, { "id": "SC3", "statement": "Selectively changing misfolded α-synuclein accumulation changes dopamine-neuron survival or disease progression, with target engagement and specificity controls.", "subclaim_type": "mechanism", "scope": "In-vivo PD-relevant contexts; native-toxin/forced-seed model evidence distinguished from clinical human PD.", "claimed_scope": "In-vivo PD-relevant contexts; native-toxin/forced-seed model evidence distinguished from clinical human PD.", "governing_rubric": "01-neurodegeneration.md", "key_evidence_anchor": "Verified harmful-species accumulation change coupled to independently measured neuron survival or disease trajectory, with specificity and mechanistically matched rescue.", "hsef_level": "Γ", "confidence": "Moderate", "governing_cap_or_threshold": "Γ system/scope and mediator-attribution boundary", "rationale": "Native protein-lowering and aggregation interventions yield model-scoped protection, but total-protein function, engineered/seed initiation and TH-marker endpoints leave the stipulated misfolded-species survival dependency unresolved; human primary trials do not supply a confirmed positive efficacy result." }, { "id": "SC4", "statement": "The direct misfolded-protein mechanism accounts for dopaminergic neuronal loss in typical human sporadic PD, rather than only familial or imposed-expression/seeding systems.", "subclaim_type": "generalization", "scope": "Typical human sporadic PD; gene, olfactory and baseline-seed subgroups described without removing null participants retrospectively.", "claimed_scope": "Typical human sporadic PD; gene, olfactory and baseline-seed subgroups described without removing null participants retrospectively.", "governing_rubric": "01-neurodegeneration.md", "key_evidence_anchor": "Convergent human identified-conformer/direct dopamine-loss evidence and mechanism-aligned perturbation/natural experiment outcomes, with sporadic heterogeneity and alternatives examined.", "hsef_level": "Γ", "confidence": "Moderate", "governing_cap_or_threshold": "Γ system/scope and mediator-attribution boundary", "rationale": "Human pathology/seeding is strong association and familial biology is causal in its own scope; no examined human instrument or selective target-engaged positive clinical perturbation identifies direct misfolded-species loss causality in typical sporadic PD. Mechanistic work carries the claim above pure association." } ], "aggregation_rule": "scope-matched", "aggregation_preregistered": true, "aggregation_rationale": "The preregistration preserves the index scope-matched rule: the full human PD causal claim is adjudicated through SC4, while familial and model-specific claims retain their own scores.", "primary_subclaim_id": "SC3", "aggregation_derivation": "SC4 is the only subclaim matching the complete typical-human-PD direct-toxicity/neuronal-loss scope; SC4 Γ fixes the overall Γ, independently of SC1 Ζ.", "aggregation_alternatives": { "weakest_link_would_return": "Γ", "primary_subclaim_would_return": "Γ", "scope_matched_would_return": "Γ", "note": "Weakest-link Γ; primary-subclaim SC3 Γ; scope-matched SC4 Γ. The same nominal result does not make the four scopes interchangeable." }, "index_rule_deviation": "Aggregation is unchanged. The decomposition is adjusted before literature scoring to preserve the exact supplied direct-neurotoxicity/causal-loss wording rather than the stronger index necessary-and-sufficient-primary-driver/extracellular account." }, "competing_models": { "models_evaluated": [ { "rank_in_tournament": 1, "model_id": "M5", "is_nominal": false, "name": "Heterogeneous PD pathways", "core_claim": "Distinct genetic, cellular and pathological routes converge on nigral vulnerability, with α-synuclein a context-dependent contributor.", "explains_what_nominal_does_not": "Accounts for source-specific burden/function, genotype or cellular-vulnerability dissociations described below.", "strongest_supporting_evidence": [ "[11], [18], [17], [13]" ], "strongest_contradictory_evidence": [ "[1], [2], [43]" ], "hsef_level_for_this_model": "Γ", "rationale": "Explains baseline-genotype and seed/inclusion heterogeneity without requiring one executioner in every patient. Familial alternative etiologies are causal within their own scopes, but the broad multi-pathway execution model is not a single demonstrated human mediator mechanism." }, { "rank_in_tournament": 1, "model_id": "M3", "is_nominal": false, "name": "Mitochondrial/lysosomal and proteostatic failure", "core_claim": "Cellular dopamine/organellar/clearance failure contributes to injury and can promote α-synuclein accumulation as a mediator or response.", "explains_what_nominal_does_not": "Accounts for source-specific burden/function, genotype or cellular-vulnerability dissociations described below.", "strongest_supporting_evidence": [ "[29], [33], [11], [14]" ], "strongest_contradictory_evidence": [ "[1], [3], [43]" ], "hsef_level_for_this_model": "Γ", "rationale": "Explains genotype, dopamine vulnerability and clearance dependencies, and permits α-synuclein injury downstream. It does not establish uniform organellar primacy across human PD; reciprocal protein–organelle feedback remains unresolved." }, { "rank_in_tournament": 3, "model_id": "M1", "is_nominal": true, "name": "Direct misfolded α-synuclein toxicity", "core_claim": "Misfolded α-synuclein is directly neurotoxic to dopaminergic neurons, and its accumulation causes the neuronal loss of Parkinson's disease.", "explains_what_nominal_does_not": "Accounts for source-specific burden/function, genotype or cellular-vulnerability dissociations described below.", "strongest_supporting_evidence": [ "[27], [26], [30], [43]" ], "strongest_contradictory_evidence": [ "[38], [24], [55], [54]" ], "hsef_level_for_this_model": "Γ", "rationale": "Direct injury is experimentally possible and human SNCA biology is causal in familial disease. The species responsible, concentration, native-function effects and typical-human-PD mediation remain unresolved; primary antibody nulls constrain clinical extrapolation without disproving intracellular toxicity." }, { "rank_in_tournament": 4, "model_id": "M2", "is_nominal": false, "name": "Inclusion sequestration can protect", "core_claim": "Some aggregation or inclusion formation sequesters harmful soluble protein/material, so total visible burden need not equal toxic exposure.", "explains_what_nominal_does_not": "Accounts for source-specific burden/function, genotype or cellular-vulnerability dissociations described below.", "strongest_supporting_evidence": [ "[50], [19]" ], "strongest_contradictory_evidence": [ "[32], [27], [26], [30]" ], "hsef_level_for_this_model": "Γ", "rationale": "Protective fibrillar action is demonstrated against one catechol exposure in culture; human sequestration remains a cross-sectional interpretation. Inclusion maturation can damage organelles. A protective storage account cannot be generalized to every Lewy inclusion or every fibril; the sign depends on species, state and cell context." }, { "rank_in_tournament": 5, "model_id": "M4", "is_nominal": false, "name": "Glial/non-cell-autonomous toxicity", "core_claim": "Host inflammatory or glial responses contribute to injury rather than all loss arising solely through direct neuron-intrinsic toxicity.", "explains_what_nominal_does_not": "Accounts for source-specific burden/function, genotype or cellular-vulnerability dissociations described below.", "strongest_supporting_evidence": [ "[35], [45], [32]" ], "strongest_contradictory_evidence": [ "[43], [27], [26]" ], "hsef_level_for_this_model": "Β", "rationale": "Inflammation after native protein suppression, glial aggregates and glial susceptibility motivate non-cell-autonomous contributors. They do not selectively perturb the glial-to-neuronal injury dependency; receptor-route results are not uniquely glial evidence. Direct neuronal assays show an exclusively indirect account is insufficient. Β reflects the examined broad glial-execution premise's association/host-response evidence rather than an asserted glial causal mechanism." } ], "tournament_summary": "Heterogeneity and organellar/vulnerability models tie as broader explanations of the shared dissociations. Direct misfolded toxicity is a supported mechanistic component, not yet a uniquely established complete human explanation. Leading vulnerability/heterogeneity and nominal broad-scope grades are Γ; the glial-execution premise is Β in this bounded inventory. Family/model-context causality is separately stated. Tournament ranking never changes the nominal score.", "study_separating_rank1_from_rank2": "No single decisive experiment separates the tied leading models. Doherty 2013 familial PRKN pathology and the patient-dose/isogenic seed-toxicity experiment constrain different alternatives; neither selects an exclusive executioner across typical human PD.", "nominal_wins_only_by_funding_artifact": false, "level_unchanged_by_tournament": true }, "evidence_inventory": [ { "citation": "Polymeropoulos MH, Lavedan C, Leroy E et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (New York, N.Y.). 1997. doi:10.1126/science.276.5321.2045", "source_pointer": "[1] PMID 9197268; DOI 10.1126/science.276.5321.2045", "relates_to_subclaims": [ "SC1" ], "favors_models": [ "familial SNCA causal biology", "toxic gain of function compatible", "altered normal function compatible" ], "evidence_class": "Strong", "system": "natural experiment", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "An SNCA mutation was identified in a large Italian kindred and three Greek families with autosomal dominant Parkinson disease. The human segregation/natural-experiment result connects altered alpha-synuclein biology to inherited disease.", "what_it_does_not_show": "It does not identify the neurotoxic conformer, isolate misfolding from altered normal protein function, or show that accumulation is the mediator of dopamine-neuron death in typical sporadic PD.", "confounders_present": [ "Variant segregation is a gene-level rather than species-selective perturbation", "Rare inherited disease scope" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Zarranz JJ, Alegre J, Gómez-Esteban JC et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Annals of neurology. 2004. doi:10.1002/ana.10795", "source_pointer": "[2] PMID 14755719; DOI 10.1002/ana.10795", "relates_to_subclaims": [ "SC1" ], "favors_models": [ "familial SNCA causal biology", "toxic gain of function compatible" ], "evidence_class": "Strong", "system": "natural experiment", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "E46K segregated in a Spanish autosomal dominant parkinsonism/dementia family: affected members and three young asymptomatic carriers had the variant, while examined controls did not. Autopsy showed severe substantia nigra atrophy and abundant alpha-synuclein Lewy pathology without Alzheimer pathology.", "what_it_does_not_show": "Segregation plus pathology does not establish a particular misfolded species as the toxic mediator or demonstrate a selective rescue of degeneration by removing that species.", "confounders_present": [ "Age-dependent expression in young carriers", "One family and mixed parkinsonism/dementia phenotype" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Chartier-Harlin MC, Kachergus J, Roumier C et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet (London, England). 2004. doi:10.1016/S0140-6736(04)17103-1", "source_pointer": "[3] PMID 15451224; DOI 10.1016/S0140-6736(04)17103-1", "relates_to_subclaims": [ "SC1" ], "favors_models": [ "familial SNCA dosage causality", "toxic abundance gain compatible" ], "evidence_class": "Strong", "system": "natural experiment", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Screening nine autosomal dominant families found an SNCA duplication in one family, confirmed by fluorescence in situ hybridization. The phenotype was relatively late-onset and slowly progressive, contrasting with the previously described severe triplication phenotype.", "what_it_does_not_show": "The comparison is not a controlled within-person reduction from triplication to duplication. Copy gain does not isolate aggregation from total protein abundance or neighboring genes.", "confounders_present": [ "Cross-family dose/phenotype comparison", "Locus rather than misfolded-species perturbation" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Ibáñez P, Bonnet AM, Débarges B et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet (London, England). 2004. doi:10.1016/S0140-6736(04)17104-3", "source_pointer": "[4] PMID 15451225; DOI 10.1016/S0140-6736(04)17104-3", "relates_to_subclaims": [ "SC1" ], "favors_models": [ "familial SNCA dosage causality", "toxic abundance gain compatible" ], "evidence_class": "Strong", "system": "natural experiment", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Screening 119 people with familial Parkinson disease identified two SNCA duplications. Carriers had a phenotype resembling typical PD, rather than the fulminant triplication phenotype.", "what_it_does_not_show": "Familial duplication does not show that measured misfolded accumulation mediates death, that Lewy bodies themselves are toxic, or that dosage explains ordinary sporadic PD.", "confounders_present": [ "Few duplication families", "Copy gain can include other locus effects" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Miller DW, Hague SM, Clarimon J et al. Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology. 2004. doi:10.1212/01.wnl.0000127517.33208.f4", "source_pointer": "[5] PMID 15159488; DOI 10.1212/01.wnl.0000127517.33208.f4", "relates_to_subclaims": [ "SC1" ], "favors_models": [ "familial SNCA dosage causality", "aggregation-linked toxic gain compatible", "proteostasis failure compatible" ], "evidence_class": "Strong", "system": "natural experiment", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "In the Iowa triplication kindred, blood alpha-synuclein and brain SNCA mRNA were approximately doubled. Brain insoluble/aggregated alpha-synuclein was disproportionately increased relative to the net soluble signal.", "what_it_does_not_show": "The inherited locus gain and postmortem biochemical readout do not isolate aggregation as the cause of neuron death or exclude effects of increased normally folded protein and co-amplified genes.", "confounders_present": [ "Postmortem survivor sampling", "Co-amplified locus and total-protein change" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Kiely AP, Asi YT, Kara E et al. α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta neuropathologica. 2013. doi:10.1007/s00401-013-1096-7", "source_pointer": "[6] PMID 23404372; DOI 10.1007/s00401-013-1096-7", "relates_to_subclaims": [ "SC1" ], "favors_models": [ "familial SNCA causal biology", "direct neuronal toxicity compatible", "glial contribution compatible", "mixed pathology compatible" ], "evidence_class": "Strong", "system": "natural experiment", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "G51D segregated in a British family and was absent in more than 4500 controls; larger SNCA rearrangements were excluded. The autopsied proband had onset at 19, severe nigral and widespread neuronal loss, neuronal alpha-synuclein inclusions and MSA-like oligodendroglial inclusions. Tau and TDP-43 copathology were also present.", "what_it_does_not_show": "The rare familial syndrome does not isolate direct neuronal toxicity from glial amplification, identify the lethal species, or explain ordinary sporadic PD. Minimal inclusions in the severely depleted nigra are not evidence that all misfolded protein was absent earlier.", "confounders_present": [ "One autopsied proband", "End-stage neuronal dropout changes visible pathology", "Tau/TDP-43 copathology" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Proukakis C, Dudzik CG, Brier T et al. A novel α-synuclein missense mutation in Parkinson disease. Neurology. 2013. doi:10.1212/WNL.0b013e31828727ba", "source_pointer": "[7] PMID 23427326; DOI 10.1212/WNL.0b013e31828727ba", "relates_to_subclaims": [ "SC1" ], "favors_models": [ "SNCA variant association candidate" ], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "The original report identified H50Q in one neuropathologically confirmed PD case and nominated it as a new SNCA missense variant.", "what_it_does_not_show": "A single case does not establish cosegregation or enrichment sufficient for pathogenicity. This report cannot be counted as an established causal SNCA allele in light of Blauwendraat 2018.", "confounders_present": [ "Single-case ascertainment", "Variant pathogenicity subsequently challenged" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Blauwendraat C, Kia DA, Pihlstrøm L et al. Insufficient evidence for pathogenicity of SNCA His50Gln (H50Q) in Parkinson's disease. Neurobiology of aging. 2018. doi:10.1016/j.neurobiolaging.2017.12.012", "source_pointer": "[8] PMID 29398121; DOI 10.1016/j.neurobiolaging.2017.12.012", "relates_to_subclaims": [ "SC1" ], "favors_models": [ "variant-specific causal heterogeneity", "H50Q noncausal alternative" ], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Primary population/case-control reanalysis of nominated SNCA mutations found H50Q in large population resources and no enrichment in PD, leading the authors to conclude that H50Q is probably not pathogenic.", "what_it_does_not_show": "The result does not refute well-supported A53T, E46K, G51D or dosage causality. It does constrain using H50Q functional models as genetically validated proof of a disease mechanism.", "confounders_present": [ "Population ascertainment and age/penetrance limits", "Variant-specific inference" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Zafar F, Valappil RA, Kim S et al. Genetic fine-mapping of the Iowan SNCA gene triplication in a patient with Parkinson's disease. NPJ Parkinson's disease. 2018. doi:10.1038/s41531-018-0054-4", "source_pointer": "[9] PMID 29928688; DOI 10.1038/s41531-018-0054-4", "relates_to_subclaims": [ "SC1" ], "favors_models": [ "familial SNCA dosage causality", "co-amplified locus contribution compatible", "aggregation-linked toxicity compatible" ], "evidence_class": "Strong", "system": "natural experiment", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "A descendant of the Iowa kindred developed parkinsonism at 41, severe cognitive decline and widespread Lewy pathology with severe substantia nigra loss. High-resolution arrays mapped a 1.7 Mb triplication, with 12 genes including SNCA and breakpoints disrupting HERC6 and CCSER1. Comparative mapping included a distinct Lister triplication case.", "what_it_does_not_show": "This natural copy-gain experiment is not SNCA-only or misfolded-species selective. Its iPSC expression measurements are not a human in-vivo rescue and are not counted here as an additional experimental toxicity study.", "confounders_present": [ "Twelve-gene triplication and disrupted flanking genes", "Same Iowa familial line as earlier studies" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Mutez E, Leprêtre F, Le Rhun E et al. SNCA locus duplication carriers: from genetics to Parkinson disease phenotypes. Human mutation. 2011. doi:10.1002/humu.21459", "source_pointer": "[10] PMID 21412942; DOI 10.1002/humu.21459", "relates_to_subclaims": [ "SC1" ], "favors_models": [ "familial dosage biology", "co-amplified locus contribution compatible" ], "evidence_class": "Strong", "system": "natural experiment", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "A previously known duplication kindred was characterized with a 4.928 Mb duplicated interval containing 31 genes. SNCA and 13 other genes had increased mRNA in studied cells. Dopamine-transporter imaging was associated with clinical disease severity.", "what_it_does_not_show": "The interval is not an isolated SNCA perturbation; peripheral/cellular expression and DaTSCAN uptake do not establish toxic misfolded mediation or histological neuron counts.", "confounders_present": [ "Large multigene interval", "DAT functional imaging rather than neuronal counts" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Doherty KM, Silveira-Moriyama L, Parkkinen L et al. Parkin disease: a clinicopathologic entity? JAMA neurology. 2013. doi:10.1001/jamaneurol.2013.172", "source_pointer": "[11] PMID 23459986; DOI 10.1001/jamaneurol.2013.172", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "heterogeneous disease routes", "mitochondrial/quality-control pathway compatible", "Lewy bodies imperfect injury proxy" ], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Five unrelated compound-heterozygous parkin cases were compared with five pathologically confirmed PD cases and four controls, matched first by age at death. Nigral neuronal loss was as severe as in PD, with relatively preserved dorsal tier; sparse Lewy bodies appeared in two of five parkin cases. Cognitive impairment was absent.", "what_it_does_not_show": "Rare or absent conventional Lewy bodies do not exclude non-inclusion aggregates, transient earlier misfolded species, or alpha-synuclein-mediated toxicity. Genetic parkin disease alone does not refute a mechanism scoped to typical sporadic PD.", "confounders_present": [ "Small end-stage autopsy series", "Conventional inclusion measurement", "Monogenic parkin scope" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Martí-Massó JF, Ruiz-Martínez J, Bolaño MJ et al. Neuropathology of Parkinson's disease with the R1441G mutation in LRRK2. Movement disorders : official journal of the Movement Disorder Society. 2009. doi:10.1002/mds.22677", "source_pointer": "[12] PMID 19735093; DOI 10.1002/mds.22677", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "heterogeneous genetic routes", "inclusions imperfect injury proxy" ], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "One R1441G LRRK2 patient had onset at 68, an 18-year levodopa-responsive course and mild nigral neuronal loss at autopsy without Lewy bodies/neurites or cytoplasmic alpha-synuclein, tau, LRRK2 or ubiquitin inclusions by the reported examination.", "what_it_does_not_show": "A conventional inclusion-negative autopsy cannot exclude all misfolded alpha-synuclein species or their earlier presence. One familial LRRK2 case cannot establish the explanation for all sporadic PD.", "confounders_present": [ "One end-stage case", "Assay sensitivity and time of sampling", "Genetic rather than typical sporadic disease" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Shahmoradian SH, Lewis AJ, Genoud C et al. Lewy pathology in Parkinson's disease consists of crowded organelles and lipid membranes. Nature neuroscience. 2019. doi:10.1038/s41593-019-0423-2", "source_pointer": "[13] PMID 31235907; DOI 10.1038/s41593-019-0423-2", "relates_to_subclaims": [ "SC2", "SC4" ], "favors_models": [ "organellar/proteostasis failure compatible", "composite inclusion model", "sequestration compatible", "toxic species compatible" ], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Correlative light/electron microscopy and tomography in human PD tissue showed alpha-synuclein-positive Lewy pathology crowded with membranes, vesicles and dysmorphic organelles; filaments were observed in many but not all inclusions. Super-resolution microscopy and lipid measurements supported lipid enrichment.", "what_it_does_not_show": "Morphology does not determine whether inclusions are harmful, protective sequestration, or consequences of organellar damage. It does not establish direct toxic misfolded-species causality.", "confounders_present": [ "Postmortem lesion selection", "Surviving-neuron sampling", "Morphology rather than species-selective perturbation" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Neumann J, Bras J, Deas E et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain : a journal of neurology. 2009. doi:10.1093/brain/awp044", "source_pointer": "[14] PMID 19286695; DOI 10.1093/brain/awp044", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "lysosomal upstream risk", "alpha-synuclein mediator compatible", "heterogeneous PD pathways" ], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "GBA mutations occurred in 33/790 British PD cases and 3/257 controls (OR3.7,95%CI 1.12–12.14). All 17 examined mutation-carrier autopsies had widespread alpha-synuclein pathology (Braak 5–6); cognitive impairment/dementia and hallucinations were frequent clinical features.", "what_it_does_not_show": "GBA risk and Lewy pathology do not identify alpha-synuclein as the causal mediator of lysosomal risk, or isolate direct neuronal toxicity from inflammation/proteostasis effects.", "confounders_present": [ "Rare-variant risk association", "Selected carrier autopsies", "Possible shared centers/cases with multinational 2009 study" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Sidransky E, Nalls MA, Aasly JO et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. The New England journal of medicine. 2009. doi:10.1056/NEJMoa0901281", "source_pointer": "[15] PMID 19846850; DOI 10.1056/NEJMoa0901281", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "lysosomal upstream risk", "alpha-synuclein mediator compatible" ], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "An original 16-center study of 5691 PD cases and 4898 controls found a strong GBA mutation association with PD (OR5.43). Broader sequencing detected mutations missed by testing only the two common alleles, including about 7% of non-Ashkenazi PD cases.", "what_it_does_not_show": "Case-control genetic risk is not a misfolded-species perturbation or proof of alpha-synuclein mediation. A lysosomal risk allele can affect several disease-relevant pathways.", "confounders_present": [ "Population and mutation-screen heterogeneity", "Case-control association", "Potential overlap with UK2009 report" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Mokretar K, Pease D, Taanman JW et al. Somatic copy number gains of α-synuclein (SNCA) in Parkinson's disease and multiple system atrophy brains. Brain : a journal of neurology. 2018. doi:10.1093/brain/awy157", "source_pointer": "[16] PMID 29917054; DOI 10.1093/brain/awy157", "relates_to_subclaims": [ "SC1", "SC4" ], "favors_models": [ "somatic SNCA risk compatible", "secondary disease-associated genomic change compatible" ], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Blinded SNCA FISH examined 40 sporadic PD brains,5 MSA brains and 25 controls. PD cases had a higher mean fraction of dopaminergic neurons with gains (0.78%vs 0.45%,P=.017); gains were inversely associated with onset age. Authors explicitly allowed either risk-factor or disease-consequence explanations.", "what_it_does_not_show": "Cross-sectional low-frequency gains are not a causal natural experiment, do not account directly for the much larger neuronal loss, and do not establish a misfolded protein mediator.", "confounders_present": [ "Selected relatively young/short-duration cases", "Low-frequency FISH measurement", "Reverse causation and neuron-survivor bias" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Siderowf A, Concha-Marambio L, Lafontant DE et al. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study. The Lancet. Neurology. 2023. doi:10.1016/S1474-4422(23)00109-6", "source_pointer": "[17] PMID 37059509; DOI 10.1016/S1474-4422(23)00109-6", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "common alpha-synuclein-associated PD biology", "heterogeneous PD pathways", "misfolded mediator compatible" ], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Cross-sectional PPMI analysis included 1123 participants:545 PD,163 controls,54 without dopaminergic deficit,51 prodromal and 310 nonmanifesting carriers. CSF SAA sensitivity for PD was 87.7% and control specificity 96.3%; LRRK2-PD positivity was 67.5% and fell to 34.7% with normal olfaction.44/51 prodromal participants were positive.", "what_it_does_not_show": "Detection of seeding-competent material is not a direct toxicity assay, a quantitative measure of brain accumulation, or a causal intervention. Positivity before clinical diagnosis supplies risk-marker timing rather than proof that seeds initiated neuronal loss.", "confounders_present": [ "Clinical/olfactory/genetic selection", "CSF in-vitro amplification rather than neuron survival", "Cross-sectional baseline comparison" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Jensen NM, Vitic Z, Antorini MR et al. Abundant non-inclusion α-synuclein pathology in Lewy body-negative LRRK2-mutant cases. Acta neuropathologica. 2025. doi:10.1007/s00401-025-02871-w", "source_pointer": "[18] PMID 40314782; DOI 10.1007/s00401-025-02871-w", "relates_to_subclaims": [ "SC2", "SC4" ], "favors_models": [ "non-inclusion alpha-synuclein pathology", "conventional Lewy-body measurement incomplete", "heterogeneous variant effects" ], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "MJF-14 PLA found non-inclusion particulate signal in all six Lewy-negative LRRK2-variant brains, compared with five Lewy-body-disease brains and six controls. Crucially, the six comprise three clinicalPD cases, one neuropathologically confirmedPSP case and two people without clinical neurodegenerative diagnoses. Signals often involved pontocerebellar/inferior-olivary regions.", "what_it_does_not_show": "These are not six PD cases or six equivalent monogenic pathogenic alleles. Signal abundance does not demonstrate direct neurotoxicity; neuronal loss was not quantified. It does not establish that every Lewy-negative genetic PD has alpha-synuclein-mediated disease.", "confounders_present": [ "Only three clinically diagnosedPD in variant group", "M1646T/N2081D and combined variants are not uniformly monogenic pathogenic mutations", "Small autopsy cohort", "PLA amplification/specificity and survivor bias" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Jensen NM, Fu Y, Betzer C et al. MJF-14 proximity ligation assay detects early non-inclusion alpha-synuclein pathology with enhanced specificity and sensitivity. NPJ Parkinson's disease. 2024. doi:10.1038/s41531-024-00841-9", "source_pointer": "[19] PMID 39613827; DOI 10.1038/s41531-024-00841-9", "relates_to_subclaims": [ "SC2", "SC4" ], "favors_models": [ "non-inclusion alpha-synuclein pathology", "sequestration compatible", "toxic non-inclusion species compatible" ], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Human component compared anterior cingulate tissue from 10 BraakIV PD,10 BraakVI PD and 10 controls, plus 2 DLB and 2 controls for selected analyses. PLA revealed abundant non-inclusion signal in both PD groups without a significant IV–VI difference. Neuron counts per sampled region did not significantly differ (P=.103); inference of earlier pathology derives from cross-sectional staging.", "what_it_does_not_show": "PLA signal is not proof that the detected species kills dopamine neurons, or that inclusions protect them. The temporal sequestration interpretation is not direct longitudinal observation. Cell-culture validation is not counted as an additional human primary report here.", "confounders_present": [ "Anterior cingulate rather than nigral dopamine neurons", "Cross-sectional stages", "PLA autofluorescence/control requirements", "MJF14 mouse beta-synuclein cross-reactivity documented" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Orrú CD, Vaughan DP, Vijiaratnam N et al. Diagnostic and prognostic value of α-synuclein seed amplification assay kinetic measures in Parkinson's disease: a longitudinal cohort study. The Lancet. Neurology. 2025. doi:10.1016/S1474-4422(25)00157-7", "source_pointer": "[20] PMID 40541208; DOI 10.1016/S1474-4422(25)00157-7", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "seeding-associated progression biomarker", "alpha-synuclein cognitive mediator compatible", "upstream/proteostasis correlation compatible" ], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Longitudinal analysis included 1631 participants across UK, PPMI and Tuebingen cohorts. Faster CSF amplification kinetics predicted cognitive decline (MoCA≤21): PPMIHR2.36(95%CI 1.60–3.46) and TuebingenHR2.17(1.07–4.41). The abstract states this prognostic association for cognition, not every progression endpoint.", "what_it_does_not_show": "A kinetic prognostic association does not show that selective removal of seeds changes disease, that kinetics quantify brain toxic dose, or that they mediate dopaminergic neuron loss. No SC3 causal dependency follows.", "confounders_present": [ "Outcome-specific association", "Residual clinical/copathology confounding", "Amplification kinetics and brain species differ", "PPMI participant reuse" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Lüth T, Gabbert C, Kleinz T et al. α-Synuclein Seeding Discriminates Between LRRK2 G2019S Variant Carriers with and Without Parkinson's Disease. Movement disorders : official journal of the Movement Disorder Society. 2026. doi:10.1002/mds.70553", "source_pointer": "[21] PMID 42806694; DOI 10.1002/mds.70553", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "heterogeneous LRRK2-associated disease", "mitochondrial/alpha-synuclein interaction compatible" ], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "The Norwegian cohort had 76 LRRK2 carriers,714 idiopathicPD and 411 controls, but CSF SAA measured only 10 LRRK2-PD,30 nonmanifesting carriers,6 controls and 56 idiopathicPD.80% of LRRK2-PD and one unaffected carrier were positive. Exploratory mitochondrial genetic burden association also used a PPMI replication component.", "what_it_does_not_show": "Full genotyped cohort counts are not SAA sample sizes. Genetic associations with SAA do not establish direct toxicity, misfolded mediation of LRRK2 risk, or a selective survival response.", "confounders_present": [ "Very small LRRK2-PD CSF subset", "Exploratory genetic burden analyses", "PPMI reuse" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Wu LY, du Toit T, Georgiades T et al. Pathology and Genetics in a Global Cohort of Parkinsonian Disorders. JAMA neurology. 2026. doi:10.1001/jamaneurol.2026.1634", "source_pointer": "[22] PMID 42258190; DOI 10.1001/jamaneurol.2026.1634", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "common Lewy-associated disease", "heterogeneous genetic pathways", "copathology contribution" ], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Original retrospective clinicopathologic/genetic analysis included 3353 eligible donors from 11 brain banks. PD/PDD/DLB clinical diagnoses had 92.0% positive predictive value for Lewy pathology;33/745 neurologically normal controls had Lewy pathology. AD copathology occurred in 426/1064 Lewy-disease cases; GBA1 carriers had more extensive Lewy burden than noncarriers/LRRK2 carriers.", "what_it_does_not_show": "Pathological prevalence or burden is not direct misfolded-species causality. Incidental Lewy pathology does not prove protection or absence of prodromal disease. Misdiagnosed clinicalPD cases should not be recast as proven alpha-synuclein-independent idiopathicPD.", "confounders_present": [ "Retrospective brain-bank selection", "Broad Lewy disease classification", "Mixed clinical diagnoses and copathology", "Likely reuse of historical donor series" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Panegyres PK, Kwok JB, Junckerstorff R. Clinicopathological characterisation of the first Australian family with the p.G51D SNCA mutation. Parkinsonism & related disorders. 2026. doi:10.1016/j.parkreldis.2026.108955", "source_pointer": "[23] PMID 42660007; DOI 10.1016/j.parkreldis.2026.108955", "relates_to_subclaims": [ "SC1" ], "favors_models": [ "familial SNCA causal biology", "variant-specific expression" ], "evidence_class": "Strong", "system": "natural experiment", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "An Australian G51D kindred showed young-onset parkinsonism and variable expression: proband motor onset 38 and cognitive symptoms 41, sisters onset 51 and 28, and a 27-year-old carrier with subtle thumb tremor. Proband autopsy showed diffuse Lewy pathology.", "what_it_does_not_show": "Independent kindred replication does not isolate the toxic conformer or supply human selective-aggregation rescue. Variable ages/features preclude an unconditional allele-to-fixed-trajectory prediction.", "confounders_present": [ "Small familial series", "Age-dependent penetrance", "Rare hereditary scope" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Blauwendraat C, Makarious MB, Leonard HL et al. A population scale analysis of rare SNCA variation in the UK Biobank. Neurobiology of disease. 2021. doi:10.1016/j.nbd.2020.105182", "source_pointer": "[24] PMID 33307186; DOI 10.1016/j.nbd.2020.105182", "relates_to_subclaims": [ "SC1" ], "favors_models": [ "age/tissue-dependent SNCA penetrance", "somatic/mosaic ascertainment alternative" ], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "UKBiobank screening of about 500000 people identified 30 SNCA copy-number events (6 duplications,6 deletions,18 complex events), many suspected mosaic. None had diagnosedPD at the reported follow-up; three had some prodromal features without meeting prodromal criteria. Seven of 18 complex events had blood cancer.", "what_it_does_not_show": "Blood mosaic gains are not established germline brain SNCA duplication and incomplete age/follow-up does not prove inherited dosage harmless. The data constrain indiscriminate penetrance claims, not all familial SNCA causality.", "confounders_present": [ "Blood-derived copy-number calls and hematologic mosaicism", "Healthy-volunteer/age-follow-up selection", "Small number of germline-like duplications" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Farrer M, Maraganore DM, Lockhart P et al. alpha-Synuclein gene haplotypes are associated with Parkinson's disease. Human molecular genetics. 2001. doi:10.1093/hmg/10.17.1847", "source_pointer": "[25] PMID 11532993; DOI 10.1093/hmg/10.17.1847", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "common SNCA-locus risk", "alpha-synuclein mediator compatible" ], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Original case-control haplotype analysis found common SNCA haplotypes associated with Parkinson disease, extending locus relevance beyond rare Mendelian coding/copy-number families.", "what_it_does_not_show": "Locus association does not establish a causal allele, valid mediation instrument, toxic conformer, or selective change in dopaminergic survival. It cannot alone cross a causal perturbation threshold.", "confounders_present": [ "Linkage disequilibrium", "Population/case-control association", "No measured toxic species" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Winner B et al. (2011). In vivo demonstration that alpha-synuclein oligomers are toxic. Proceedings of the National Academy of Sciences of the United States of America. DOI: 10.1073/pnas.1100976108.", "source_pointer": "[26] PMID 21325059; DOI 10.1073/pnas.1100976108", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [ "M1", "M2" ], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Oligomer-promoting variants cause greater dopaminergic neuronal loss than fast fibril-forming variants. NeuN comparisons support actual loss; even weaker-promoter expression exceeded familial triplication levels, and unrelated HET-s aggregates were not similarly toxic.", "what_it_does_not_show": "Mutation changes can alter membrane/function properties as well as assembly; does not identify a universal native sporadic-PD toxic species.", "confounders_present": [ "Ectopic variants/expression", "Conformer-function confounding", "Model exposure", "Expression above familial triplication even under weaker promoter" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Karpinar DP et al. (2009). Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. The EMBO journal. DOI: 10.1038/emboj.2009.257.", "source_pointer": "[27] PMID 19745811; DOI 10.1038/emboj.2009.257", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [ "M1", "M2" ], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Prefibrillar variants associate with increased neuronal toxicity and behavioral defects across model systems.", "what_it_does_not_show": "Biophysical convergence does not separate all normal-function changes; not spontaneous human dopamine-neuron loss.", "confounders_present": [ "Engineered sequence", "Expression levels", "Nonmammalian scope" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Xu J et al. (2002). Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nature medicine. DOI: 10.1038/nm0602-600.", "source_pointer": "[28] PMID 12042811; DOI 10.1038/nm0602-600", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [ "M1", "M3", "M5" ], "evidence_class": "Weak", "system": "in vitro", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Dopaminergic apoptosis depends on endogenous dopamine and ROS; soluble alpha-syn/14-3-3 complexes are implicated, whereas cortical neurons show protection.", "what_it_does_not_show": "Does not establish fibrils or inclusions as the harmful species, ordinary in vivo exposure, or sporadic progression mediation.", "confounders_present": [ "Cultured accumulation", "Complex composition/conformation unresolved", "Neuron-type/state differences" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Mosharov EV et al. (2009). Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron. DOI: 10.1016/j.neuron.2009.01.033.", "source_pointer": "[29] PMID 19409267; DOI 10.1016/j.neuron.2009.01.033", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [ "M1", "M3", "M5" ], "evidence_class": "Weak", "system": "in vitro", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Snca deletion protects against L-DOPA-induced death without reducing cytosolic dopamine; calcium/dopamine differences confer SN susceptibility.", "what_it_does_not_show": "Identifies alpha-syn-dependent vulnerability, not a particular misfolded toxic species or an exclusively protein-first process.", "confounders_present": [ "Dopamine challenge", "Constitutive knockout adaptation", "Normal function versus misfolding" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Luk KC et al. (2012). Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science (New York, N.Y.). DOI: 10.1126/science.1227157.", "source_pointer": "[30] PMID 23161999; DOI 10.1126/science.1227157", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [ "M1", "M5" ], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Seeded pathology progresses with selective SNpc dopamine-neuron loss, reduced dopamine and motor deficits, while adjacent VTA is spared. PBS/monomer and Snca-null recipients lack the same pathology/DA-loss outcome; not all gross/open-field motor outcomes change.", "what_it_does_not_show": "Does not establish spontaneous sporadic initiation, isolate one conformer or rule out indirect/glial mediators. Main-text loss estimates are TH-defined; complete supplemental stereological details not audited.", "confounders_present": [ "Synthetic seed dose/injury", "Route versus intracellular toxicity", "Selective susceptibility" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Volpicelli-Daley LA et al. (2011). Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron. DOI: 10.1016/j.neuron.2011.08.033.", "source_pointer": "[31] PMID 21982369; DOI 10.1016/j.neuron.2011.08.033", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [ "M1", "M3" ], "evidence_class": "Weak", "system": "in vitro", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "PFFs recruit native alpha-syn into Lewy-like pathology with synaptic/electrical deficits and later neuronal death.", "what_it_does_not_show": "Neuron death is not specifically human dopaminergic loss; forced initiation and indirect culture effects remain.", "confounders_present": [ "PFF exposure", "Non-dopaminergic neuronal scope", "Culture maturation" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Mahul-Mellier AL et al. (2020). The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America. DOI: 10.1073/pnas.1913904117.", "source_pointer": "[32] PMID 32075919; DOI 10.1073/pnas.1913904117", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [ "M1", "M3", "M4" ], "evidence_class": "Weak", "system": "in vitro", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Inclusion maturation coincides with organelle sequestration, mitochondrial/synaptic disruption and later death beyond early fibrillization. Snca-null cultures do not show PFF-associated death; glial TUNEL precedes later neuronal NeuN/TUNEL death.", "what_it_does_not_show": "Temporal stages alone do not fully isolate causality; is not proof that every mature inclusion is protective or toxic in human PD. Earlier glial injury leaves non-cell-autonomous contribution possible.", "confounders_present": [ "Forced seed", "Correlated maturation processes", "Primary neuron subtype" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Grassi D et al. (2018). Identification of a highly neurotoxic α-synuclein species inducing mitochondrial damage and mitophagy in Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America. DOI: 10.1073/pnas.1713849115.", "source_pointer": "[33] PMID 29487216; DOI 10.1073/pnas.1713849115", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [ "M1", "M3" ], "evidence_class": "Weak", "system": "in vitro", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Incomplete aggregate degradation generates a distinct nonfibrillar fragment associated with mitochondrial damage, energetic stress and mitophagy.", "what_it_does_not_show": "Cannot infer all injury is direct from localization; selective native conformer depletion and human degeneration mediation are not established in accessed abstract.", "confounders_present": [ "Seeded model", "Autophagy perturbation pleiotropy", "Conformer antibody/processing specificity" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Dauer W et al. (2002). Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. Proceedings of the National Academy of Sciences of the United States of America. DOI: 10.1073/pnas.172514599.", "source_pointer": "[34] PMID 12376616; DOI 10.1073/pnas.172514599", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [ "M1", "M3" ], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Knockout resists dopamine-neuron degeneration; resistance tracks inability of MPTP to inhibit complex I rather than abnormal dopamine-transporter function.", "what_it_does_not_show": "Deletion changes normal protein biology and toxin response; no isolated misfolded-species removal.", "confounders_present": [ "Developmental adaptation", "Toxin metabolism/action", "Normal function instrument" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Benskey MJ et al. (2018). Silencing Alpha Synuclein in Mature Nigral Neurons Results in Rapid Neuroinflammation and Subsequent Toxicity. Frontiers in molecular neuroscience. DOI: 10.3389/fnmol.2018.00036.", "source_pointer": "[35] PMID 29497361; DOI 10.3389/fnmol.2018.00036", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [ "M3", "M4", "M5" ], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": true, "direction": "contradicts", "what_it_shows": "Suppression precedes MHC-I induction, microglial/T-cell recruitment and later nigrostriatal neuronal loss; control hairpin/cerebellar exposure does not reproduce injury.", "what_it_does_not_show": "Does not prove every suppression strategy is unsafe or exclude shRNA/dose effects; no exclusive misfolded gain-of-function instrument.", "confounders_present": [ "RNAi expression/dose", "Vector/hairpin toxicity", "Inflammatory mediation" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Zharikov AD et al. (2015). shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model. The Journal of clinical investigation. DOI: 10.1172/JCI64502.", "source_pointer": "[36] PMID 26075822; DOI 10.1172/JCI64502", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [ "M1", "M3", "M5" ], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Partial knockdown is tolerated at baseline and protects rotenone-exposed nigral neurons/terminals while attenuating motor deficits. Blinded counts co-label TH, MAP2 and nuclei; functional/neuritic protection accompanies counts.", "what_it_does_not_show": "Total protein reduction changes normal function and aggregation substrate simultaneously; does not selectively identify a misfolded toxic species. Count inclusion requires TH positivity, so it is not an independent Nissl-only rescue measure.", "confounders_present": [ "Total-protein manipulation", "Rotenone context", "RNAi specificity/degree" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Zharikov A et al. (2019). Long-term RNAi knockdown of α-synuclein in the adult rat substantia nigra without neurodegeneration. Neurobiology of disease. DOI: 10.1016/j.nbd.2019.01.004.", "source_pointer": "[37] PMID 30658149; DOI 10.1016/j.nbd.2019.01.004", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [ "M3", "M5" ], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": true, "direction": "null", "what_it_shows": "Strong long-term knockdown shows no Nissl-defined neuron loss or significant motor dysfunction; TH declines with both vectors.", "what_it_does_not_show": "Tolerance in this delivery context does not prove universal safety or disease rescue. TH-positive count alone can conflate phenotype suppression with death.", "confounders_present": [ "Vector/hairpin effects", "Degree/time of depletion", "Unchallenged context" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Cole TA et al. (2021). α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease. JCI insight. DOI: 10.1172/jci.insight.135633.", "source_pointer": "[38] PMID 33682798; DOI 10.1172/jci.insight.135633", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [ "M1", "M3", "M5" ], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "ASOs reduce pathology and preserve TH-positive counts; some pretreatment paradigms normalize dopamine. Transient post-seed treatment later preserves TH despite increased aggregate counts.", "what_it_does_not_show": "Examined survival estimates are TH-based, without separate pan-neuronal counts; total-protein lowering is not misfolded-specific. Behavioral improvement is a trend in the accessed mouse paradigm.", "confounders_present": [ "TH phenotype versus survival", "Total substrate reduction", "PFF initiation", "Species/paradigm differences" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Mao X et al. (2016). Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science (New York, N.Y.). DOI: 10.1126/science.aah3374.", "source_pointer": "[39] PMID 27708076; DOI 10.1126/science.aah3374", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [ "M1", "M5" ], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Lag3 loss delays PFF-associated dopaminergic loss and biochemical/behavioral deficits. In vivo TH/Nissl stereology and dopamine/motor outcomes improve; cultured KO-to-re-expression rescue, PI/NeuN and calcium assays strengthen a model-specific uptake-to-injury dependency.", "what_it_does_not_show": "Route dependence does not establish a mandatory extracellular mechanism for all PD or isolate intrinsic conformer toxicity; receptor expression/specificity is contested. Global Lag3 deletion also affects T-cell homeostasis; it is not a neuronal-specific knockout.", "confounders_present": [ "LAG3 expression/assay dispute", "Immune receptor effects", "PFF context", "Global receptor deletion/altered T-cell homeostasis" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Emmenegger M et al. (2021). LAG3 is not expressed in human and murine neurons and does not modulate α-synucleinopathies. EMBO molecular medicine. DOI: 10.15252/emmm.202114745.", "source_pointer": "[40] PMID 34309222; DOI 10.15252/emmm.202114745", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [ "M3", "M5" ], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": true, "direction": "null", "what_it_shows": "No neuronal expression detected; inducible LAG3 does not increase human-culture seeding, knockout does not change A53T survival or slice pathology.", "what_it_does_not_show": "Different model/region from Mao nigrostriatal PFF experiment; not a direct refutation of all alpha-syn toxicity or all uptake routes.", "confounders_present": [ "Detection limits", "A53T motor/survival versus dopamine-neuron loss", "Culture/slice route differences" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Wegrzynowicz M et al. (2019). Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model. Acta neuropathologica. DOI: 10.1007/s00401-019-02023-x.", "source_pointer": "[41] PMID 31165254; DOI 10.1007/s00401-019-02023-x", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [ "M1", "M3", "M5" ], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Aggregation-profile modulation restores dopamine release and preserves TH counts/gait; baseline nigral degeneration is NeuN-confirmed. Dense clusters/HMW signal decrease while dispersed small species increase.", "what_it_does_not_show": "Treatment rescue counts examined are TH-based; off-target aggregation-modulator effects and artificial substrate remain. Small species are not automatically the harmful oligomers of another assay.", "confounders_present": [ "Truncated transgene/native-null background", "Drug specificity", "TH treatment endpoint", "Species identity across assays" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Chen Y et al. (2019). Engineering synucleinopathy-resistant human dopaminergic neurons by CRISPR-mediated deletion of the SNCA gene. The European journal of neuroscience. DOI: 10.1111/ejn.14286.", "source_pointer": "[42] PMID 30472757; DOI 10.1111/ejn.14286", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [ "M1", "M5" ], "evidence_class": "Weak", "system": "in vitro", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Reduced/absent SNCA alleles resist pS129 Lewy-like pathology.", "what_it_does_not_show": "Accessed abstract does not show neuron-loss rescue; a seeding-resistant graft candidate is not established protection in human PD.", "confounders_present": [ "Pathology-only endpoint", "Developmental editing", "PFF challenge" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Tanudjojo B et al. (2021). Phenotypic manifestation of α-synuclein strains derived from Parkinson's disease and multiple system atrophy in human dopaminergic neurons. Nature communications. DOI: 10.1038/s41467-021-23682-z.", "source_pointer": "[43] PMID 34155194; DOI 10.1038/s41467-021-23682-z", "relates_to_subclaims": [ "SC1", "SC2", "SC3", "SC4" ], "favors_models": [ "M1", "M3", "M5" ], "evidence_class": "Weak", "system": "in vitro", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Brain-amplified strains produce dose/strain-dependent death in triplication neurons, reversed by isogenic dosage normalization. Similar early seeding does not imply equal later toxicity.", "what_it_does_not_show": "Does not establish identical toxicity in normal-dose sporadic neurons; amplification may select conformers and gene-dose rescue is not misfolded-selective depletion.", "confounders_present": [ "Familial dosage", "PMCA conformer selection", "In vitro exposure", "Shared maturation susceptibility" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Kinet R et al. (2025). Differential pathological dynamics triggered by distinct Parkinson patient-derived α-synuclein extracts in nonhuman primates. Science advances. DOI: 10.1126/sciadv.adu6050.", "source_pointer": "[44] PMID 40531987; DOI 10.1126/sciadv.adu6050", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [ "M1", "M3", "M5" ], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Equal-total-alpha-syn LA/SA patient fractions yield different time courses and similar later TH-defined nigrostriatal deficits. SA contains small amyloid assemblies, so its former noLB label does not mean no pathological alpha-syn.", "what_it_does_not_show": "Not spontaneous human causality or alpha-syn-specific fraction toxicity: extract cofactors, sonication, untreated rather than matched extract controls and partial endpoint audit remain. Prior 24-month findings are reused.", "confounders_present": [ "Extract cofactors", "Forced delivery", "Small primate cohorts", "Report/cohort overlap", "Reuse of previously reported24-month observations", "SA/noLB contains small aggregates", "No alpha-syn immunodepletion rescue in accessed design" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Schmidt SI et al. (2025). Formation of seeding-competent α-synuclein aggregates in parkin-deficient iPSC-derived human neurons. NPJ Parkinson's disease. DOI: 10.1038/s41531-025-01038-4.", "source_pointer": "[45] PMID 40541955; DOI 10.1038/s41531-025-01038-4", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [ "M1", "M3", "M4", "M5" ], "evidence_class": "Weak", "system": "in vitro", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Parkin deficiency increases native aggregated/released/seeding-competent alpha-syn and synaptic/Ca2+ abnormalities, including dopamine-neuronal and astrocytic aggregates.", "what_it_does_not_show": "No alpha-syn-selective rescue establishes mediation or direct neuron death; PARK2 changes clearance/organellar biology upstream. Lewy-body absence cannot be equated with absence of soluble/pathological alpha-syn.", "confounders_present": [ "Parkin pleiotropy", "Mixed neuronal/glial cells", "Synaptic rather than cell-loss endpoint" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Kuan WL et al. (2023). Selective neurodegeneration generated by intravenous α-synuclein pre-formed fibril administration is not associated with endogenous α-synuclein levels in the rat brain. Brain pathology (Zurich, Switzerland). DOI: 10.1111/bpa.13128.", "source_pointer": "[46] PMID 36321260; DOI 10.1111/bpa.13128", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [ "M1", "M3", "M5" ], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Specific midbrain dopamine and other neuronal populations are lost, without association to region-level native alpha-syn expression.", "what_it_does_not_show": "Regional expression is not single-cell exposure or genetic deletion; result does not prove alpha-syn-independent degeneration or ordinary spontaneous delivery.", "confounders_present": [ "RVG9R carrier/dose", "Region-level abundance", "No selective native conformer suppression" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Fusco G et al. (2017). Structural basis of membrane disruption and cellular toxicity by α-synuclein oligomers. Science (New York, N.Y.). DOI: 10.1126/science.aan6160.", "source_pointer": "[47] PMID 29242346; DOI 10.1126/science.aan6160", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [ "M1" ], "evidence_class": "Weak", "system": "in vitro", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Lipophilic membrane interaction and bilayer insertion define toxic oligomer properties; targeted mutation reduces cellular toxicity.", "what_it_does_not_show": "Membrane/toxicity mechanism is plausible but exposure, normal-function effects and human dopamine-cell specificity are unproven.", "confounders_present": [ "Artificial oligomer preparation", "Sequence-function confounding", "Non-dopaminergic assay" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Cascella R et al. (2021). The release of toxic oligomers from α-synuclein fibrils induces dysfunction in neuronal cells. Nature communications. DOI: 10.1038/s41467-021-21937-3.", "source_pointer": "[48] PMID 33753734; DOI 10.1038/s41467-021-21937-3", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [ "M1", "M2" ], "evidence_class": "Weak", "system": "in vitro", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Fibrils release toxic soluble oligomers; shorter fibrils cause greater immediate dysfunction consistent with more ends.", "what_it_does_not_show": "Aggregate categories are kinetically interconverting; direct human dopamine-neuron loss or ordinary concentration is not established.", "confounders_present": [ "Artificial concentration/assembly", "Cellular dysfunction versus in vivo survival", "Released species identification" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Gorbatyuk OS et al. (2010). In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration. Molecular therapy : the journal of the American Society of Gene Therapy. DOI: 10.1038/mt.2010.115.", "source_pointer": "[49] PMID 20551914; DOI 10.1038/mt.2010.115", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [ "M3", "M5" ], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "contradicts", "what_it_shows": "Suppression produces marker-confirmed cell loss, striatal dopamine depletion and behavioral asymmetry; protein re-expression partially reverses injury.", "what_it_does_not_show": "Does not show misfolded accumulation removal is harmful, or invalidate all reduction therapies; vector/hairpin specificity, suppression level and rescue dose matter.", "confounders_present": [ "RNAi/vector context", "Normal protein depletion", "Ectopic rescue" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Carmo-Gonçalves P et al. (2020). In Vitro Protective Action of Monomeric and Fibrillar α-Synuclein on Neuronal Cells Exposed to the Dopaminergic Toxins Salsolinol and DOPAL. ACS chemical neuroscience. DOI: 10.1021/acschemneuro.0c00527.", "source_pointer": "[50] PMID 33080132; DOI 10.1021/acschemneuro.0c00527", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [ "M2", "M3", "M5" ], "evidence_class": "Weak", "system": "in vitro", "decisive_perturbation": false, "endogenous": false, "direction": "contradicts", "what_it_shows": "Monomer protects against both catechols; fibrils improve DOPAL but not salsolinol viability, with potentially less-toxic DOPAL adduct formation.", "what_it_does_not_show": "Not proof Lewy-body sequestration protects in human PD; response depends on toxin and assembly and may reflect chemical trapping rather than native intracellular storage.", "confounders_present": [ "Artificial protein/toxin exposure", "Catechol chemistry", "Culture-specific protection" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Pagano G et al. Trial of Prasinezumab in Early-Stage Parkinson's Disease. The New England journal of medicine. 2022. DOI: 10.1056/NEJMoa2202867; PMID: 35921451.", "source_pointer": "[51] PMID 35921451; DOI 10.1056/NEJMoa2202867", "relates_to_subclaims": [ "SC3", "SC4" ], "favors_models": [ "M5" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "null", "what_it_shows": "PASADENA randomized 316 early PD participants; neither prasinezumab dose met the global MDS-UPDRS primary endpoint, and dopamine-transporter imaging did not differ substantially from placebo.", "what_it_does_not_show": "Does not show disease modification or neuron survival; it tests extracellular antibody treatment after clinical diagnosis rather than selective removal of intracellular toxic conformers.", "confounders_present": [ "Clinical symptoms do not directly count surviving dopaminergic neurons", "Extracellular/free-CSF target does not establish intracellular toxic-species depletion", "Small safety cohorts or endpoint/subgroup/external comparator limits as described" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Pagano G et al. Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease. Nature medicine. 2024. DOI: 10.1038/s41591-024-02886-y; PMID: 38622249.", "source_pointer": "[52] PMID 38622249; DOI 10.1038/s41591-024-02886-y", "relates_to_subclaims": [ "SC3", "SC4" ], "favors_models": [ "M1", "M5" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Exploratory analyses of PASADENA baseline-defined subpopulations found a larger numerical motor-sign effect in groups expected to progress faster.", "what_it_does_not_show": "These secondary analyses follow a failed primary endpoint; subgroup definitions were prespecified, but the effect interpretation remains exploratory and requires independent randomized confirmation.", "confounders_present": [ "Clinical symptoms do not directly count surviving dopaminergic neurons", "Extracellular/free-CSF target does not establish intracellular toxic-species depletion", "Small safety cohorts or endpoint/subgroup/external comparator limits as described" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Pagano G et al. Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial. Nature medicine. 2024. DOI: 10.1038/s41591-024-03270-6; PMID: 39379705.", "source_pointer": "[53] PMID 39379705; DOI 10.1038/s41591-024-03270-6", "relates_to_subclaims": [ "SC3", "SC4" ], "favors_models": [ "M1", "M5" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "PASADENA open-label extension participants had slower motor-score deterioration than a weighted external PPMI comparator over four years.", "what_it_does_not_show": "No concurrent placebo beyond the first year; selection, residual confounding, medication differences, examiner/placebo effects and cohort mismatch can explain some or all of the contrast; no direct neuronal survival or misfolded-species mediation.", "confounders_present": [ "Clinical symptoms do not directly count surviving dopaminergic neurons", "Extracellular/free-CSF target does not establish intracellular toxic-species depletion", "Small safety cohorts or endpoint/subgroup/external comparator limits as described" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Nikolcheva T et al. Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study. Lancet (London, England). 2026. DOI: 10.1016/S0140-6736(26)00865-2; PMID: 42208564.", "source_pointer": "[54] PMID 42208564; DOI 10.1016/S0140-6736(26)00865-2", "relates_to_subclaims": [ "SC3", "SC4" ], "favors_models": [ "M1", "M5" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "null", "what_it_shows": "PADOVA randomized 586 early PD participants on stable symptomatic medication; the primary motor-event endpoint was not met (HR 0.84, 95% CI 0.69–1.01; p=0.066), with prespecified exploratory signals favoring further study.", "what_it_does_not_show": "A suggestive effect is not a positive primary trial or proof of neuroprotection/direct toxicity; the July 2026 erratum corrects the appendix but its detailed impact is unresolved because the corrected appendix was not examined.", "confounders_present": [ "Clinical symptoms do not directly count surviving dopaminergic neurons", "Extracellular/free-CSF target does not establish intracellular toxic-species depletion", "Small safety cohorts or endpoint/subgroup/external comparator limits as described" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Lang AE et al. Trial of Cinpanemab in Early Parkinson's Disease. The New England journal of medicine. 2022. DOI: 10.1056/NEJMoa2203395; PMID: 35921450.", "source_pointer": "[55] PMID 35921450; DOI 10.1056/NEJMoa2203395", "relates_to_subclaims": [ "SC3", "SC4" ], "favors_models": [ "M5" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "null", "what_it_shows": "SPARK randomized 357 early PD participants; no cinpanemab dose improved clinical progression or DaT-SPECT versus placebo, and the trial was stopped for lack of efficacy.", "what_it_does_not_show": "No inference that every intracellular misfolded species was effectively neutralized; failure of this extracellular antibody does not establish lack of any alpha-synuclein contribution.", "confounders_present": [ "Clinical symptoms do not directly count surviving dopaminergic neurons", "Extracellular/free-CSF target does not establish intracellular toxic-species depletion", "Small safety cohorts or endpoint/subgroup/external comparator limits as described" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Hutchison RM et al. Cinpanemab in Early Parkinson Disease: Evaluation of Biomarker Results From the Phase 2 SPARK Clinical Trial. Neurology. 2024. DOI: 10.1212/WNL.0000000000209137; PMID: 38315945.", "source_pointer": "[56] PMID 38315945; DOI 10.1212/WNL.0000000000209137", "relates_to_subclaims": [ "SC3", "SC4" ], "favors_models": [ "M5" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "null", "what_it_shows": "SPARK biomarker analyses confirmed seeds in most of the baseline CSF subgroup, but neither clinical nor imaging/fluid biomarkers showed a cinpanemab treatment effect.", "what_it_does_not_show": "Baseline seeding positivity is disease classification, not toxic-species dependence or direct neuron killing; no substantial reduction of the measured seed signal was demonstrated.", "confounders_present": [ "Clinical symptoms do not directly count surviving dopaminergic neurons", "Extracellular/free-CSF target does not establish intracellular toxic-species depletion", "Small safety cohorts or endpoint/subgroup/external comparator limits as described" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Eijsvogel P et al. Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial. Nature medicine. 2024. DOI: 10.1038/s41591-024-03101-8; PMID: 38902546.", "source_pointer": "[57] PMID 38902546; DOI 10.1038/s41591-024-03101-8", "relates_to_subclaims": [ "SC3", "SC4" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "UB-312 phase 1 PD vaccination induced antibodies in serum and a subset of CSF samples; exploratory seed-amplification maximum fluorescence fell in one active dose group. Randomized groups did not differ statistically on clinical scales.", "what_it_does_not_show": "The small safety/immunogenicity trial does not establish clinical benefit or neuronal preservation. Post-treatment antibody-positive subgroup contrasts are nonrandomized, and antibody effects on the amplification assay require separation from depletion of brain toxic species.", "confounders_present": [ "Clinical symptoms do not directly count surviving dopaminergic neurons", "Extracellular/free-CSF target does not establish intracellular toxic-species depletion", "Small safety cohorts or endpoint/subgroup/external comparator limits as described" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Volc D et al. Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial. The Lancet. Neurology. 2020. DOI: 10.1016/S1474-4422(20)30136-8; PMID: 32562684.", "source_pointer": "[58] PMID 32562684; DOI 10.1016/S1474-4422(20)30136-8", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "PD01A dose-randomized phase 1 PD immunization and extensions showed a humoral response that could be reactivated with booster dosing and acceptable tolerability over follow-up.", "what_it_does_not_show": "Dose comparison without a placebo efficacy contrast cannot demonstrate slowed degeneration; immunogenicity and inferred engagement do not isolate the proposed toxic mediator.", "confounders_present": [ "Clinical symptoms do not directly count surviving dopaminergic neurons", "Extracellular/free-CSF target does not establish intracellular toxic-species depletion", "Small safety cohorts or endpoint/subgroup/external comparator limits as described" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Poewe W et al. Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson's Disease: A Randomized, Placebo-Controlled, Phase 1 Study. Journal of Parkinson's disease. 2021. DOI: 10.3233/JPD-212594; PMID: 34092654.", "source_pointer": "[59] PMID 34092654; DOI 10.3233/JPD-212594", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "PD03A placebo-controlled phase 1 PD vaccination generated anti-peptide and alpha-synuclein-specific antibodies with acceptable tolerability.", "what_it_does_not_show": "The safety study was not powered for clinical efficacy; no significant clinical-scale or striatal DAT-SPECT contrast, and symptomatic medication changes limit interpretation of clinical trends.", "confounders_present": [ "Clinical symptoms do not directly count surviving dopaminergic neurons", "Extracellular/free-CSF target does not establish intracellular toxic-species depletion", "Small safety cohorts or endpoint/subgroup/external comparator limits as described" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Buur L et al. Randomized Phase I Trial of the α-Synuclein Antibody Lu AF82422. Movement disorders : official journal of the Movement Disorder Society. 2024. DOI: 10.1002/mds.29784; PMID: 38494847.", "source_pointer": "[60] PMID 38494847; DOI 10.1002/mds.29784", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Single-dose Lu AF82422 reduced plasma free alpha-synuclein and the CSF free-to-total ratio in the high-dose PD cohort, supporting central compartment engagement.", "what_it_does_not_show": "Free/total ratio modulation does not demonstrate removal of neuron-intrinsic misfolded species, neuronal survival, or a clinical trajectory effect.", "confounders_present": [ "Clinical symptoms do not directly count surviving dopaminergic neurons", "Extracellular/free-CSF target does not establish intracellular toxic-species depletion", "Small safety cohorts or endpoint/subgroup/external comparator limits as described" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Shering C et al. Phase 1, randomized trials of MEDI1341: cerebrospinal fluid free α-synuclein lowered by >50. Brain communications. 2025. DOI: 10.1093/braincomms/fcaf304; PMID: 40936651.", "source_pointer": "[61] PMID 40936651; DOI 10.1093/braincomms/fcaf304", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "MEDI1341 randomized phase 1 healthy and PD studies measured dose-dependent lowering of CSF free alpha-synuclein; the highest PD dose reduced the median CSF-free signal by 59.0% at Day85.", "what_it_does_not_show": "Target binding/sequestration lowers the free assay signal; it does not establish reduction of total pathogenic tissue burden or clinical disease modification. Read Methods/Results show no notable clinical treatment-group trends.", "confounders_present": [ "Clinical symptoms do not directly count surviving dopaminergic neurons", "Extracellular/free-CSF target does not establish intracellular toxic-species depletion", "Small safety cohorts or endpoint/subgroup/external comparator limits as described" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Liu Y et al. Quantification of cinpanemab (BIIB054) binding to α-synuclein in cerebrospinal fluid of phase 1 single ascending dose samples. The Journal of pharmacology and experimental therapeutics. 2025. DOI: 10.1124/jpet.124.002199; PMID: 39892989.", "source_pointer": "[62] PMID 39892989; DOI 10.1124/jpet.124.002199", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Crosslink-stabilized assays of cinpanemab phase 1 samples directly detected dose- and time-dependent drug–alpha-synuclein complexes in human CSF.", "what_it_does_not_show": "This corrects an absolute claim that CNS engagement was never measured, but does not demonstrate intracellular aggregate depletion or efficacy in the separate SPARK trial.", "confounders_present": [ "Clinical symptoms do not directly count surviving dopaminergic neurons", "Extracellular/free-CSF target does not establish intracellular toxic-species depletion", "Small safety cohorts or endpoint/subgroup/external comparator limits as described" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Schenk DB et al. First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers. Movement disorders : official journal of the Movement Disorder Society. 2017. DOI: 10.1002/mds.26878; PMID: 27886407.", "source_pointer": "[63] PMID 27886407; DOI 10.1002/mds.26878", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Single-dose PRX002 in healthy participants produced dose-dependent reductions of free serum alpha-synuclein with favorable phase 1 tolerability.", "what_it_does_not_show": "Peripheral serum binding in healthy participants gives no neuronal-survival or PD progression evidence; total signal increased after binding.", "confounders_present": [ "Clinical symptoms do not directly count surviving dopaminergic neurons", "Extracellular/free-CSF target does not establish intracellular toxic-species depletion", "Small safety cohorts or endpoint/subgroup/external comparator limits as described" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Brys M et al. Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054. Movement disorders : official journal of the Movement Disorder Society. 2019. DOI: 10.1002/mds.27738; PMID: 31211448.", "source_pointer": "[64] PMID 31211448; DOI 10.1002/mds.27738", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Cinpanemab phase 1 healthy/PD study measured dose-proportional exposure and plasma complexes; CSF drug levels were a small fraction of serum levels.", "what_it_does_not_show": "The original phase 1 assay could not measure CSF complexes; this was subsequently resolved by the 2025 assay report from the same study, rather than representing two independent clinical experiments.", "confounders_present": [ "Clinical symptoms do not directly count surviving dopaminergic neurons", "Extracellular/free-CSF target does not establish intracellular toxic-species depletion", "Small safety cohorts or endpoint/subgroup/external comparator limits as described" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" }, { "citation": "Jankovic J et al. Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial. JAMA neurology. 2018. DOI: 10.1001/jamaneurol.2018.1487; PMID: 29913017.", "source_pointer": "[65] PMID 29913017; DOI 10.1001/jamaneurol.2018.1487", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Multiple-dose PRX002 in PD reduced free serum alpha-synuclein and produced dose-dependent CSF drug exposure with generally favorable phase 1 tolerability.", "what_it_does_not_show": "CSF exposure was predicted to engage extracellular aggregates, rather than demonstrating their selective clearance or neuronal preservation.", "confounders_present": [ "Clinical symptoms do not directly count surviving dopaminergic neurons", "Extracellular/free-CSF target does not establish intracellular toxic-species depletion", "Small safety cohorts or endpoint/subgroup/external comparator limits as described" ], "verification": "verified", "verification_note": "Examined primary record on 2026-10-03; source-specific access depth and limitation in ledger. Verification confirms the bounded source result, not its broader interpretation.", "citation_context": { "retrieved": false, "supporting_count": null, "mentioning_count": null, "contrasting_count": null, "notable_contrasting_statements": [ "No citation-context counts retrieved." ] }, "source_tier": "A" } ], "verification_summary": { "load_bearing_claims_checked": 65, "verified": 65, "unverified": 0, "contradicted": 0, "note": "Each source carries a bounded examined-result claim. None asserts that source retrieval independently validates disease causality. PADOVA appendix correction scope remains unresolved; the review relies only on its current primary abstract for the bounded primary-endpoint result." }, "factual_issues_found": [], "cap_rules_applied": [ { "subclaim_id": "SC2", "cap": "Γ", "cap_source": "universal", "triggered": true, "trigger_text_quoted": "Overexpression in model systems caps at Γ", "specific_trigger": "Conformer-mutant and ectopic expression results support artificial direct toxicity, not endogenous human dopamine-neuron loss.", "resulting_ceiling": "Γ" }, { "subclaim_id": "SC2", "cap": "Γ", "cap_source": "universal", "triggered": true, "trigger_text_quoted": "In vitro evidence alone cannot exceed Γ.", "specific_trigger": "Patient-derived/isogenic conformer-exposure findings establish cell-system causality rather than organismal survival dependency.", "resulting_ceiling": "Γ" }, { "subclaim_id": "SC3", "cap": "Γ", "cap_source": "universal", "triggered": true, "trigger_text_quoted": "Biomarker change without functional/phenotypic change caps at Γ.", "specific_trigger": "Human phase 1 drug binding, free-CSF signal or seed-assay changes without a randomized disease-trajectory benefit do not cross the human contribution boundary.", "resulting_ceiling": "Γ" }, { "subclaim_id": "SC4", "cap": "Γ", "cap_source": "universal", "triggered": true, "trigger_text_quoted": "Overexpression in model systems caps at Γ", "specific_trigger": "Engineered neuronal models are not the complete typical-human-PD explanation.", "resulting_ceiling": "Γ" }, { "subclaim_id": "SC4", "cap": "Γ", "cap_source": "universal", "triggered": true, "trigger_text_quoted": "In vitro evidence alone cannot exceed Γ.", "specific_trigger": "Identified-conformer human cell toxicity has no matched organismal human survival follow-through.", "resulting_ceiling": "Γ" }, { "subclaim_id": "SC4", "cap": "Β", "cap_source": "universal", "triggered": false, "trigger_text_quoted": "Pure association evidence — however large, however replicated — cannot exceed Β.", "specific_trigger": "This applies to the isolated human pathology/seed-assay leg; it is not reapplied to the full mechanistic evidence set.", "resulting_ceiling": "Β" } ], "cap_precedence_resolutions": [ { "collision": "Native Snca suppression or deletion crosses a model-level causal threshold, while the toxic-species/direct-human claim remains unresolved.", "subclaim_scope_cap_binds_on": "SC2/SC3/SC4 misfolded-species direct survival mechanism and typical-human sporadic PD.", "subclaim_scope_threshold_binds_on": "Native protein requirement in a specific toxin or forced-seed model; engineered aggregation-dependent injury in its stated cell/animal context.", "resolution": "A perturbation crosses within its actual system. Total-protein removal changes both normal function and misfolding substrate; artificial initiation and TH-only protection cannot be silently promoted to selectively demonstrated misfolded-species neuron-survival dependence. A contextual model Δ/Ε does not automatically raise SC4.", "note": "No obligatory endogenous propagation premise is imposed: forced-seeding caps constrain spontaneous disease generalization, not whether a seed can injure its recipient." } ], "boundary_check_BGD": [ { "subclaim_id": "SC1", "field_valid_perturbation_quote": "Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism. Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo; Selective pathway inhibition that changes onset/progression while preserving broader viability", "qualifying_evidence_present": "yes", "qualifying_evidence_citation": "[1], [2], [3], [4], [5]", "gamma_hard_rules_triggered": [ "\"In vitro aggregation alone\": not triggered as the complete subclaim basis; human native-genotype natural experiments qualify.", "\"In vitro seeding alone\": not triggered as the complete subclaim basis; human native-genotype natural experiments qualify.", "\"Droplet aging in vitro\": not triggered as the complete subclaim basis; human native-genotype natural experiments qualify.", "\"Organoid toxicity without organismal follow-through\": not triggered as the complete subclaim basis; human native-genotype natural experiments qualify.", "\"Exogenous seeding models alone\": not triggered as the complete subclaim basis; human native-genotype natural experiments qualify." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "yes", "perturbation_result_note": "Positive native-genotype natural experiments establish familial SNCA disease biology.", "ceiling_from_boundary_check": "Δ or higher" }, { "subclaim_id": "SC2", "field_valid_perturbation_quote": "Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism. Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo; Selective pathway inhibition that changes onset/progression while preserving broader viability", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "[27], [26], [43], [36], [38], [54], [55]", "gamma_hard_rules_triggered": [ "\"In vitro aggregation alone\": not triggered as the complete set: injury/native-genotype and non-seed protein-dependency data exceed this isolated class; imposed exposure and specificity limits are assessed separately.", "\"In vitro seeding alone\": not triggered as the complete set: injury/native-genotype and non-seed protein-dependency data exceed this isolated class; imposed exposure and specificity limits are assessed separately.", "\"Droplet aging in vitro\": not triggered: no selected droplet/organoid-only evidence basis.", "\"Organoid toxicity without organismal follow-through\": not triggered: no selected droplet/organoid-only evidence basis.", "\"Exogenous seeding models alone\": not triggered as the complete set: injury/native-genotype and non-seed protein-dependency data exceed this isolated class; imposed exposure and specificity limits are assessed separately." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Positive results exist within restricted models and cells, but no examined positive perturbation satisfies all of this subclaim's species, specificity, phenotype and claimed-scope premises; absence of a qualifying positive is not equivalent to biological refutation.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC3", "field_valid_perturbation_quote": "Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism. Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo; Selective pathway inhibition that changes onset/progression while preserving broader viability", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "[27], [26], [43], [36], [38], [54], [55]", "gamma_hard_rules_triggered": [ "\"In vitro aggregation alone\": not triggered as the complete set: injury/native-genotype and non-seed protein-dependency data exceed this isolated class; imposed exposure and specificity limits are assessed separately.", "\"In vitro seeding alone\": not triggered as the complete set: injury/native-genotype and non-seed protein-dependency data exceed this isolated class; imposed exposure and specificity limits are assessed separately.", "\"Droplet aging in vitro\": not triggered: no selected droplet/organoid-only evidence basis.", "\"Organoid toxicity without organismal follow-through\": not triggered: no selected droplet/organoid-only evidence basis.", "\"Exogenous seeding models alone\": not triggered as the complete set: injury/native-genotype and non-seed protein-dependency data exceed this isolated class; imposed exposure and specificity limits are assessed separately." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Positive results exist within restricted models and cells, but no examined positive perturbation satisfies all of this subclaim's species, specificity, phenotype and claimed-scope premises; absence of a qualifying positive is not equivalent to biological refutation.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC4", "field_valid_perturbation_quote": "Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism. Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo; Selective pathway inhibition that changes onset/progression while preserving broader viability", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "[27], [26], [43], [36], [38], [54], [55]", "gamma_hard_rules_triggered": [ "\"In vitro aggregation alone\": not triggered as the complete set: injury/native-genotype and non-seed protein-dependency data exceed this isolated class; imposed exposure and specificity limits are assessed separately.", "\"In vitro seeding alone\": not triggered as the complete set: injury/native-genotype and non-seed protein-dependency data exceed this isolated class; imposed exposure and specificity limits are assessed separately.", "\"Droplet aging in vitro\": not triggered: no selected droplet/organoid-only evidence basis.", "\"Organoid toxicity without organismal follow-through\": not triggered: no selected droplet/organoid-only evidence basis.", "\"Exogenous seeding models alone\": not triggered as the complete set: injury/native-genotype and non-seed protein-dependency data exceed this isolated class; imposed exposure and specificity limits are assessed separately." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Positive results exist within restricted models and cells, but no examined positive perturbation satisfies all of this subclaim's species, specificity, phenotype and claimed-scope premises; absence of a qualifying positive is not equivalent to biological refutation.", "ceiling_from_boundary_check": "Γ" } ], "thresholds_tested": [ { "subclaim_id": "SC1", "threshold": "Δ", "requirement_quoted": "Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.", "satisfied": "yes", "supporting_evidence": [ "[1], [2], [3], [4], [5], [9], [24], [8]" ], "what_would_cross_it": "" }, { "subclaim_id": "SC1", "threshold": "Ε", "requirement_quoted": "Requires causal support in a defined context, but with clear restriction by subtype, disease stage, model, or tissue.", "satisfied": "yes", "supporting_evidence": [ "[1], [2], [3], [4], [5], [9], [24], [8]" ], "what_would_cross_it": "" }, { "subclaim_id": "SC1", "threshold": "Ζ", "requirement_quoted": "Multiple independent causal lines in vivo; Replication across at least two relevant systems; Narrowing of major alternative models", "satisfied": "yes", "supporting_evidence": [ "[1], [2], [3], [4], [5], [9], [24], [8]" ], "what_would_cross_it": "" }, { "subclaim_id": "SC1", "threshold": "Η", "requirement_quoted": "Strong convergent causal evidence across systems; Intervention-sensitive change in trajectory; No major unresolved contradiction about whether the mechanism is upstream versus downstream", "satisfied": "no", "supporting_evidence": [ "[1], [2], [3], [4], [5], [9], [24], [8]" ], "what_would_cross_it": "Selective SNCA-linked trajectory intervention/natural withdrawal-rescue in the established familial context, with penetrance and co-duplicated-locus alternatives resolved." }, { "subclaim_id": "SC2", "threshold": "Δ", "requirement_quoted": "Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.", "satisfied": "no", "supporting_evidence": [ "[27], [26], [43], [36], [38], [54]" ], "what_would_cross_it": "A positive matched-control intervention isolates the identified misfolded species at physiological exposure, preserves normal protein function and changes independently measured dopaminergic survival or sustained clinical disease trajectory; replicate at the stated scope." }, { "subclaim_id": "SC3", "threshold": "Δ", "requirement_quoted": "Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.", "satisfied": "no", "supporting_evidence": [ "[27], [26], [43], [36], [38], [54]" ], "what_would_cross_it": "A positive matched-control intervention isolates the identified misfolded species at physiological exposure, preserves normal protein function and changes independently measured dopaminergic survival or sustained clinical disease trajectory; replicate at the stated scope." }, { "subclaim_id": "SC4", "threshold": "Δ", "requirement_quoted": "Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.", "satisfied": "no", "supporting_evidence": [ "[27], [26], [43], [36], [38], [54]" ], "what_would_cross_it": "A positive matched-control intervention isolates the identified misfolded species at physiological exposure, preserves normal protein function and changes independently measured dopaminergic survival or sustained clinical disease trajectory; replicate at the stated scope." } ], "generalization_check": { "generalization_tested": "yes", "context_boundary_mapped": "yes", "internal_negative_controls": [ "[24] population carriers without diagnosed PD; mosaicism and observation-time limits prevent a uniform penetrance claim.", "[43] patient dosage/isogenic versus healthy neuronal vulnerability under amplified-seed exposure.", "[11], [18], [17] genetic/pathological and assay heterogeneity; non-inclusion signal detection is not direct toxic dependency." ], "note": "Mapped contextual native-gene/model effects can warrant contextual Ε; they do not establish SC4 causal contribution in typical sporadic PD. Baseline genotypes and assay strata can be prospectively described, but post-treatment antibody-positive responders are not a new claimed population." }, "falsification_patterns_met": [], "pitfalls_flagged": [ { "subclaim_id": "SC4", "pitfall": "2. Association dressed as mechanism", "where": "Pathology and seed positivity are not evidence that the detected conformer executes neuron death." }, { "subclaim_id": "SC2", "pitfall": "3. Overexpression treated as endogenous mechanism", "where": "Conformer and truncated-transgene studies carry explicit exposure and system limits." }, { "subclaim_id": "SC3", "pitfall": "8. Confirmation by biomarker", "where": "Free-CSF binding, seed-amplification fluorescence, TH expression and neuron survival are distinct endpoints." }, { "subclaim_id": "SC4", "pitfall": "16. Failed generalization mistaken for weak evidence", "where": "Native protein dependence in a toxin context is reported as context causality rather than as a human toxic-species causal proof." }, { "subclaim_id": "SC4", "pitfall": "21. A universal cap re-applied to a convergent evidence set", "where": "Familial natural experiments are scored on their own terms; no associational leg is used to erase those data." }, { "subclaim_id": "SC4", "pitfall": "22. Scope fitted to the result", "where": "Post-treatment CSF antibody-positive UB-312 participants cannot retrospectively define the human claim." } ], "causal_tally_audit": { "tally_claimed_by_document": 16, "tally_after_audit": 15, "items_rejected": [ "MI2 anle138b (PMID31165254) is a positive phenotype/aggregation intervention but the substrate is an artificial truncated transgene on Snca-null background; it is not counted in the audited endogenous-dependency report tally.", "Forced seeds/ectopic conformer experiments remain informative capability evidence but do not count as direct human endogenous-initiated causal survival studies.", "TH preservation without independent pan-neuronal counts is not relabeled demonstrated survival.", "Peripheral/CSF antibody binding or biomarker movement alone is not a decisive phenotype perturbation.", "Repeated family and PASADENA/SPARK reports are not additional independent causal lines." ], "note": "Audited number counts native-family/model dependency reports, including opposing results and imposed-model contexts; it is not an independent-study or complete-human-toxic-species causal tally. No positive complete SC4 selective survival dependency is established." }, "steelman": { "case_one_rung_higher": "The strongest Δ case combines human SNCA coding/dosage natural experiments, direct injury caused by conformer-specific manipulations, dose-corrected patient neuron rescue and native protein lowering that protects dopaminergic systems. It can be argued that orthogonal genetics, species exposure and perturbation identify α-synuclein as a contributing toxic driver without demanding universal necessity, sufficiency or extracellular primacy. PADOVA's favorable estimate and exploratory prasinezumab signals are compatible with that contribution.", "case_one_rung_lower": "The strongest Β case limits the human sporadic evidence to pathology and diagnostic seeding, treats familial mutants as a separate etiology and observes no confirmed positive primary clinical trial. Direct toxic-species causality in ordinary human PD could then be described as association only.", "which_rejected": "Both alternatives are rejected for the full scope: Δ lacks a qualifying positive human or equivalent endogenous toxic-species survival instrument; Β discards reproducible direct conformer-injury and rescue capabilities supporting a mechanistic causal model.", "blocking_cap_threshold_or_missing_experiment": "The named blocker for Δ is mediator-specific, target-engaged dopamine-neuron survival or sustained disease rescue while preserving normal α-synuclein function at relevant exposure. Total SNCA gene causality, artificial conformer exposure and exploratory clinical signals do not fill that conjunction; they nevertheless anchor Γ above Β." }, "final_score": { "hsef_level": "Γ", "hsef_descriptor": "Mechanistically plausible, partial system support", "confidence": "Moderate", "confidence_rationale": "The mechanistic capability is supported across approaches and clinical primary results are verified against retrieved primary abstracts. Toxic-species assignment, physiology/exposure dependence, reused cohorts, partial full-text access and unresolved corrected-appendix details limit confidence in the full human scope; this is an evidence/access band, not a probability that α-synuclein is harmless.", "rests_on_non_peer_reviewed_work": false, "rationale": "Scope-matched preregistration yields SC4 Γ for the full human direct-toxicity/PD-loss claim; SC1 Ζ for familial SNCA biology is preserved separately. The examined causal work establishes more than association, but does not yet isolate the specified endogenous human toxic mediator and survival dependency. Null trials are not treated as complete mechanistic refutations." }, "role_of_mechanism": { "classification": "epiphenomenon", "derivation_step_matched": "2", "derivation": "At the full typical-human-PD direct toxic-species scope, the examined evidence does not isolate either degeneration-produced-misfolding or misfolding-produced-neuron-loss dependency. The framework's step 2 therefore assigns its operational category epiphenomenon. This means the broad human causal role is unresolved, not that α-synuclein biology is inert: familial SNCA biology is causal, and experimentally demonstrated toxicity/amplification remains possible.", "tournament_used_as_tiebreaker": false, "note": "A model-scoped reinforcing role and familial gene-level driver role must not be silently promoted to one full-human-PD role. The operational category is explicitly distinguished from a biological claim of dispensability." }, "extended_scoring_MSD": { "momentum": { "value": "Decisive work underway", "artifact": "PARAISO NCT07174310: randomized phase 3 prasinezumab/placebo trial, recruiting registry checked 2026-10-03 (last update 2026-09-03), motor-event primary endpoint with at least 104 weeks observation.", "justification": "A controlled clinical outcome with demonstrable disease-relevant target engagement could cross the human contribution boundary; registry plans are outside the examined peer-reviewed report count." }, "stability": { "value": "Uncertain", "trigger": "A confirmed positive primary clinical result with verified pathogenic-species engagement and degeneration mediation could raise SC3/SC4; effective intracellular toxic-species clearance with no survival/trajectory effect at adequate exposure would lower the relevant direct causal claim. PARAISO is an ongoing program, with estimated primary completion 2029-06-30, rather than a completed result.", "justification": "Named plausible findings can point both directions. A symptomatic benefit or an extracellular antibody null without effective mediator blockade would not alone settle direct intracellular toxicity." }, "divergence": { "implied_level": "Δ", "implied_level_basis": "Representative clinical primary-report framing (PD01A PMID32562684: α-synuclein pathology as a driver of neuronal dysfunction; PASADENA/SPARK background framing of a pathogenic role) invites a causal driver interpretation. This bounded sample of framing is not a survey of all field opinion.", "assessed_level": "Γ", "gap_in_rungs": 1, "value": "Mild overstatement", "justification": "Representative implied Δ minus assessed Γ is +1 rung. More cautious primary authors explicitly describe exploratory findings and unresolved efficacy." }, "calibration_note": "M/S/D assigned last and never alter grade/confidence; live registry status is a momentum artifact, not grade-fixing primary evidence." }, "change_record": { "applies": false, "prior_level": "not consulted", "prior_confidence": null, "prior_source": null, "derived_before_consulting_prior": true, "new_level": "Γ", "direction": "newly assigned", "what_moved_it": "Fresh evidence-derived assignment under the preregistered user wording; earlier scored website reviews were not consulted.", "divergence_from_other_reviewers": null }, "proposed_decisive_experiments": [ { "name": "Endogenous conformer depletion and matched reinstatement", "experiment": "In a physiological SNCA-expression PD-relevant system, selectively remove a molecularly defined harmful conformer while preserving monomeric synaptic function, then restore only that conformer without raising total protein or causing nonspecific proteostatic injury.", "readout": "Orthogonal conformer abundance/occupancy, longitudinal dopaminergic neuron lineage survival, pan-neuronal counts, dopamine physiology and sustained function.", "critical_control": "Toxicity and efficacy independent of TH expression; equal soluble protein/function controls, inactive reagent, matched conformer versus nontoxic species rescue and blinded exposure/timing.", "falsifying_result": "Effective specific conformer removal leaves independently measured neuron loss unchanged, and matched reinstatement does not restore injury.", "supporting_result": "Selective removal preserves neurons and matched harmful-conformer reinstatement restores loss, with a nontoxic species failing to do so." }, { "name": "Controlled human target engagement with causal-loss mediation", "experiment": "Preregister baseline PD/genotype/seed strata and an adequate clinical horizon; randomize an intervention with validated engagement of the proposed intracellular/extracellular toxic species and an orthogonal normal-function-preserving strategy.", "readout": "Primary disease trajectory, a validated degeneration endpoint and pathogenic-species engagement measured separately; causal mediation addressing symptoms, inflammation and total-protein effects.", "critical_control": "Do not define responders after treatment; free CSF signal or seeding fluorescence is not automatically quantitative brain conformer removal; independently validate the degeneration endpoint.", "falsifying_result": "Verified adequate harmful-species depletion without clinical/degeneration improvement under prespecified exposure and stage.", "supporting_result": "A replicated primary trajectory/degeneration benefit explained by the selective toxic mediator rather than symptomatic or general anti-inflammatory action." } ], "knowledge_gaps": [ { "name": "Toxic entity and burden", "statement": "Oligomers, short fibrils, seeding-competent material, inclusion maturation and total insoluble burden are not interchangeable causal entities.", "relevance": "The therapeutic perturbation must identify what is actually removed." }, { "name": "Normal function and dopamine context", "statement": "Protein reduction can protect in one system and harm in another, while cytosolic dopamine, calcium and clearance govern vulnerability.", "relevance": "Controls must discriminate toxic gain of function from altered physiological function." }, { "name": "Human direct loss mediation", "statement": "Seed diagnosis, neuropathology, dopamine-marker changes and clinical symptoms do not independently demonstrate direct molecular execution of neuron death.", "relevance": "This is the SC4 causal boundary." }, { "name": "Correction and cohort scope", "statement": "The amended PADOVA appendix and exact global participant overlap across cohort reports were not fully audited.", "relevance": "Limits claims about detailed trial methods and independent study counts." } ], "review_metadata": { "review_date": "2026-10-03", "reviewer": "Codex", "evidence_base_note": "65 distinct primary reports actually examined: 25 focused partial full-text examinations and 40 abstracts/metadata; no full-paper/supplement audit claimed. Bounded primary-source search, not an exhaustive systematic review.", "literature_tools_available": true, "literature_tools_note": "SciSpace semantic searches used for discovery; clinical methodological add-column returned 0/3 extractable records and is saved. PubMed/Entrez and Europe PMC/publisher primary sources used for independent records. NEJM publisher text was blocked, so primary trial results there remain abstract-level. No citation-context counts retrieved.", "skill_version": "5.3", "validator_run": "pass", "validator_warnings_addressed": "The sole v5.claim_form conjunction warning is explicitly justified in Reviewer notes: exact supplied causal conjunction retained and graded through four unconditional subclaims and preregistered aggregation. No topic or phenomenon is graded.", "consensus_consistency_audit": "2026-10-09; supplementary provenance/source reconciliation; original grading retained; prior grades visible." }, "is_calibration_entry": { "value": false, "entry_role": "not_calibration", "blind_graded": null, "completed_blinded_calibration": false, "expected_band_sealed_at": "", "target_sha256": "", "target_authorship": "not applicable", "target_author_saw_review": null, "future_run_status": "not prepared", "unblinded_reason": "" }, "upper_ladder_check": { "final_level_below_zeta": true, "equivalents_considered": [ { "kind": "mendelian_randomization", "available": false, "why_not_sufficient": "No examined valid instrument isolates the identified misfolded species and direct nigral loss in typical sporadic disease independently of total protein/function." }, { "kind": "natural_experiment", "available": true, "why_not_sufficient": "Familial SNCA coding/dosage experiments establish SC1 gene-level causality and are not re-capped, but do not identify the conformer or generalize it automatically to sporadic direct loss." }, { "kind": "dose_response_across_populations", "available": true, "why_not_sufficient": "Familial copy-number/phenotype gradients are informative but total expression, related family reports, penetrance and co-duplicated genes limit misfolded-mediator attribution." }, { "kind": "withdrawal_rechallenge", "available": true, "why_not_sufficient": "Native knockdown/re-expression models distinguish normal-function dependence and model toxicity, not matched removal/restoration of the endogenous human misfolded mediator." }, { "kind": "therapeutic_perturbation_hard_endpoint", "available": true, "why_not_sufficient": "SPARK/PASADENA/PADOVA did not meet primary clinical efficacy endpoints; exploratory and uncontrolled contrasts remain hypothesis-generating. Phase 1 engagement has no confirmed disease rescue." } ], "convergence_present": false, "cap_reapplied_to_convergent_set": false }, "provenance_header": { "sources_total": 65, "claims_total": 65, "claims_verified": 65, "claims_unverified": 0, "claims_contradicted": 0, "tier_a_sources": 65, "generated_by": "Codex; HSEF v5.3", "gate_passed": true }, "claims": [ { "id": "C1", "text": "An SNCA mutation was identified in a large Italian kindred and three Greek families with autosomal dominant Parkinson disease. The human segregation/natural-experiment result connects altered alpha-synuclein biology to inherited disease.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 1 ], "verification": "verified", "verified_against": "abstract_metadata: Complete PubMed abstract and linked status fields examined; article body and supplements not examined.", "verified_on": "2026-10-03", "note": "It does not identify the neurotoxic conformer, isolate misfolding from altered normal protein function, or show that accumulation is the mediator of dopamine-neuron death in typical sporadic PD." }, { "id": "C2", "text": "E46K segregated in a Spanish autosomal dominant parkinsonism/dementia family: affected members and three young asymptomatic carriers had the variant, while examined controls did not. Autopsy showed severe substantia nigra atrophy and abundant alpha-synuclein Lewy pathology without Alzheimer pathology.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 2 ], "verification": "verified", "verified_against": "abstract_metadata: Complete PubMed abstract and linked status fields examined; article body and supplements not examined.", "verified_on": "2026-10-03", "note": "Segregation plus pathology does not establish a particular misfolded species as the toxic mediator or demonstrate a selective rescue of degeneration by removing that species." }, { "id": "C3", "text": "Screening nine autosomal dominant families found an SNCA duplication in one family, confirmed by fluorescence in situ hybridization. The phenotype was relatively late-onset and slowly progressive, contrasting with the previously described severe triplication phenotype.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 3 ], "verification": "verified", "verified_against": "abstract_metadata: Complete PubMed abstract and linked status fields examined; article body and supplements not examined.", "verified_on": "2026-10-03", "note": "The comparison is not a controlled within-person reduction from triplication to duplication. Copy gain does not isolate aggregation from total protein abundance or neighboring genes." }, { "id": "C4", "text": "Screening 119 people with familial Parkinson disease identified two SNCA duplications. Carriers had a phenotype resembling typical PD, rather than the fulminant triplication phenotype.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 4 ], "verification": "verified", "verified_against": "abstract_metadata: Complete PubMed abstract and linked status fields examined; article body and supplements not examined.", "verified_on": "2026-10-03", "note": "Familial duplication does not show that measured misfolded accumulation mediates death, that Lewy bodies themselves are toxic, or that dosage explains ordinary sporadic PD." }, { "id": "C5", "text": "In the Iowa triplication kindred, blood alpha-synuclein and brain SNCA mRNA were approximately doubled. Brain insoluble/aggregated alpha-synuclein was disproportionately increased relative to the net soluble signal.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 5 ], "verification": "verified", "verified_against": "abstract_metadata: Complete PubMed abstract and linked status fields examined; article body and supplements not examined.", "verified_on": "2026-10-03", "note": "The inherited locus gain and postmortem biochemical readout do not isolate aggregation as the cause of neuron death or exclude effects of increased normally folded protein and co-amplified genes." }, { "id": "C6", "text": "G51D segregated in a British family and was absent in more than 4500 controls; larger SNCA rearrangements were excluded. The autopsied proband had onset at 19, severe nigral and widespread neuronal loss, neuronal alpha-synuclein inclusions and MSA-like oligodendroglial inclusions. Tau and TDP-43 copathology were also present.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 6 ], "verification": "verified", "verified_against": "full_text_partial: Complete PubMed abstract plus full Materials and methods and Results, including genotype, clinical history, neuronal loss and neuronal/glial pathology, were examined; Discussion and supplements were not fully examined.", "verified_on": "2026-10-03", "note": "The rare familial syndrome does not isolate direct neuronal toxicity from glial amplification, identify the lethal species, or explain ordinary sporadic PD. Minimal inclusions in the severely depleted nigra are not evidence that all misfolded protein was absent earlier." }, { "id": "C7", "text": "The original report identified H50Q in one neuropathologically confirmed PD case and nominated it as a new SNCA missense variant.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 7 ], "verification": "verified", "verified_against": "abstract_metadata: Entire short PubMed abstract and identity/status metadata examined. Europe PMC fullTextXML request for PMC3653201 returned HTTP500; body was not examined.", "verified_on": "2026-10-03", "note": "A single case does not establish cosegregation or enrichment sufficient for pathogenicity. This report cannot be counted as an established causal SNCA allele in light of Blauwendraat 2018." }, { "id": "C8", "text": "Primary population/case-control reanalysis of nominated SNCA mutations found H50Q in large population resources and no enrichment in PD, leading the authors to conclude that H50Q is probably not pathogenic.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 8 ], "verification": "verified", "verified_against": "abstract_metadata: Complete PubMed abstract and linked status metadata examined. Europe PMC fullTextXML request for PMC5823280 returned HTTP500; body/supplements were not examined.", "verified_on": "2026-10-03", "note": "The result does not refute well-supported A53T, E46K, G51D or dosage causality. It does constrain using H50Q functional models as genetically validated proof of a disease mechanism." }, { "id": "C9", "text": "A descendant of the Iowa kindred developed parkinsonism at 41, severe cognitive decline and widespread Lewy pathology with severe substantia nigra loss. High-resolution arrays mapped a 1.7 Mb triplication, with 12 genes including SNCA and breakpoints disrupting HERC6 and CCSER1. Comparative mapping included a distinct Lister triplication case.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 9 ], "verification": "verified", "verified_against": "full_text_partial: Complete abstract and full Results and Methods were examined, including clinical/autopsy findings, copy-number mapping and expression methods; Discussion and supplements not fully read. Human natural experiment is the counted component.", "verified_on": "2026-10-03", "note": "This natural copy-gain experiment is not SNCA-only or misfolded-species selective. Its iPSC expression measurements are not a human in-vivo rescue and are not counted here as an additional experimental toxicity study." }, { "id": "C10", "text": "A previously known duplication kindred was characterized with a 4.928 Mb duplicated interval containing 31 genes. SNCA and 13 other genes had increased mRNA in studied cells. Dopamine-transporter imaging was associated with clinical disease severity.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 10 ], "verification": "verified", "verified_against": "abstract_metadata: Complete PubMed abstract and linked status fields examined; article body and supplements not examined.", "verified_on": "2026-10-03", "note": "The interval is not an isolated SNCA perturbation; peripheral/cellular expression and DaTSCAN uptake do not establish toxic misfolded mediation or histological neuron counts." }, { "id": "C11", "text": "Five unrelated compound-heterozygous parkin cases were compared with five pathologically confirmed PD cases and four controls, matched first by age at death. Nigral neuronal loss was as severe as in PD, with relatively preserved dorsal tier; sparse Lewy bodies appeared in two of five parkin cases. Cognitive impairment was absent.", "carries_number": false, "load_bearing_for": [ "SC4" ], "source_ns": [ 11 ], "verification": "verified", "verified_against": "abstract_metadata: Complete structured PubMed abstract and status metadata examined. Europe PMC fullTextXML request for PMC4202385 returned HTTP500; full Methods/Results not examined.", "verified_on": "2026-10-03", "note": "Rare or absent conventional Lewy bodies do not exclude non-inclusion aggregates, transient earlier misfolded species, or alpha-synuclein-mediated toxicity. Genetic parkin disease alone does not refute a mechanism scoped to typical sporadic PD." }, { "id": "C12", "text": "One R1441G LRRK2 patient had onset at 68, an 18-year levodopa-responsive course and mild nigral neuronal loss at autopsy without Lewy bodies/neurites or cytoplasmic alpha-synuclein, tau, LRRK2 or ubiquitin inclusions by the reported examination.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 12 ], "verification": "verified", "verified_against": "abstract_metadata: Complete PubMed abstract and linked status fields examined; article body and supplements not examined.", "verified_on": "2026-10-03", "note": "A conventional inclusion-negative autopsy cannot exclude all misfolded alpha-synuclein species or their earlier presence. One familial LRRK2 case cannot establish the explanation for all sporadic PD." }, { "id": "C13", "text": "Correlative light/electron microscopy and tomography in human PD tissue showed alpha-synuclein-positive Lewy pathology crowded with membranes, vesicles and dysmorphic organelles; filaments were observed in many but not all inclusions. Super-resolution microscopy and lipid measurements supported lipid enrichment.", "carries_number": false, "load_bearing_for": [ "SC2", "SC4" ], "source_ns": [ 13 ], "verification": "verified", "verified_against": "abstract_metadata: Complete PubMed abstract and linked status fields examined; article body and supplements not examined.", "verified_on": "2026-10-03", "note": "Morphology does not determine whether inclusions are harmful, protective sequestration, or consequences of organellar damage. It does not establish direct toxic misfolded-species causality." }, { "id": "C14", "text": "GBA mutations occurred in 33/790 British PD cases and 3/257 controls (OR3.7,95%CI 1.12–12.14). All 17 examined mutation-carrier autopsies had widespread alpha-synuclein pathology (Braak 5–6); cognitive impairment/dementia and hallucinations were frequent clinical features.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 14 ], "verification": "verified", "verified_against": "abstract_metadata: Complete PubMed abstract and linked status fields examined; article body and supplements not examined.", "verified_on": "2026-10-03", "note": "GBA risk and Lewy pathology do not identify alpha-synuclein as the causal mediator of lysosomal risk, or isolate direct neuronal toxicity from inflammation/proteostasis effects." }, { "id": "C15", "text": "An original 16-center study of 5691 PD cases and 4898 controls found a strong GBA mutation association with PD (OR5.43). Broader sequencing detected mutations missed by testing only the two common alleles, including about 7% of non-Ashkenazi PD cases.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 15 ], "verification": "verified", "verified_against": "abstract_metadata: Complete PubMed abstract and linked status fields examined; article body and supplements not examined.", "verified_on": "2026-10-03", "note": "Case-control genetic risk is not a misfolded-species perturbation or proof of alpha-synuclein mediation. A lysosomal risk allele can affect several disease-relevant pathways." }, { "id": "C16", "text": "Blinded SNCA FISH examined 40 sporadic PD brains,5 MSA brains and 25 controls. PD cases had a higher mean fraction of dopaminergic neurons with gains (0.78%vs 0.45%,P=.017); gains were inversely associated with onset age. Authors explicitly allowed either risk-factor or disease-consequence explanations.", "carries_number": true, "load_bearing_for": [ "SC1", "SC4" ], "source_ns": [ 16 ], "verification": "verified", "verified_against": "abstract_metadata: Complete PubMed abstract and linked status fields examined; article body and supplements not examined.", "verified_on": "2026-10-03", "note": "Cross-sectional low-frequency gains are not a causal natural experiment, do not account directly for the much larger neuronal loss, and do not establish a misfolded protein mediator." }, { "id": "C17", "text": "Cross-sectional PPMI analysis included 1123 participants:545 PD,163 controls,54 without dopaminergic deficit,51 prodromal and 310 nonmanifesting carriers. CSF SAA sensitivity for PD was 87.7% and control specificity 96.3%; LRRK2-PD positivity was 67.5% and fell to 34.7% with normal olfaction.44/51 prodromal participants were positive.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 17 ], "verification": "verified", "verified_against": "abstract_metadata: Complete structured PubMed abstract and linked status fields examined. PMC10627170 fullTextXML request returned HTTP500; full protocol and supplements were not examined.", "verified_on": "2026-10-03", "note": "Detection of seeding-competent material is not a direct toxicity assay, a quantitative measure of brain accumulation, or a causal intervention. Positivity before clinical diagnosis supplies risk-marker timing rather than proof that seeds initiated neuronal loss." }, { "id": "C18", "text": "MJF-14 PLA found non-inclusion particulate signal in all six Lewy-negative LRRK2-variant brains, compared with five Lewy-body-disease brains and six controls. Crucially, the six comprise three clinicalPD cases, one neuropathologically confirmedPSP case and two people without clinical neurodegenerative diagnoses. Signals often involved pontocerebellar/inferior-olivary regions.", "carries_number": true, "load_bearing_for": [ "SC2", "SC4" ], "source_ns": [ 18 ], "verification": "verified", "verified_against": "full_text_partial: Complete abstract, full Materials and methods and Results, and cohort Table 1 examined. Discussion/supplements not fully read; quantitative loss was not performed by authors.", "verified_on": "2026-10-03", "note": "These are not six PD cases or six equivalent monogenic pathogenic alleles. Signal abundance does not demonstrate direct neurotoxicity; neuronal loss was not quantified. It does not establish that every Lewy-negative genetic PD has alpha-synuclein-mediated disease." }, { "id": "C19", "text": "Human component compared anterior cingulate tissue from 10 BraakIV PD,10 BraakVI PD and 10 controls, plus 2 DLB and 2 controls for selected analyses. PLA revealed abundant non-inclusion signal in both PD groups without a significant IV–VI difference. Neuron counts per sampled region did not significantly differ (P=.103); inference of earlier pathology derives from cross-sectional staging.", "carries_number": true, "load_bearing_for": [ "SC2", "SC4" ], "source_ns": [ 19 ], "verification": "verified", "verified_against": "full_text_partial: Complete abstract plus human tissue/PLA Methods; DLB and PD human Results; and mouse specificity-control Results examined. Other cell-culture/neuronal validation and all supplements not fully read; counted only original human component.", "verified_on": "2026-10-03", "note": "PLA signal is not proof that the detected species kills dopamine neurons, or that inclusions protect them. The temporal sequestration interpretation is not direct longitudinal observation. Cell-culture validation is not counted as an additional human primary report here." }, { "id": "C20", "text": "Longitudinal analysis included 1631 participants across UK, PPMI and Tuebingen cohorts. Faster CSF amplification kinetics predicted cognitive decline (MoCA≤21): PPMIHR2.36(95%CI 1.60–3.46) and TuebingenHR2.17(1.07–4.41). The abstract states this prognostic association for cognition, not every progression endpoint.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 20 ], "verification": "verified", "verified_against": "abstract_metadata: Complete PubMed abstract and linked status fields examined; article body and supplements not examined.", "verified_on": "2026-10-03", "note": "A kinetic prognostic association does not show that selective removal of seeds changes disease, that kinetics quantify brain toxic dose, or that they mediate dopaminergic neuron loss. No SC3 causal dependency follows." }, { "id": "C21", "text": "The Norwegian cohort had 76 LRRK2 carriers,714 idiopathicPD and 411 controls, but CSF SAA measured only 10 LRRK2-PD,30 nonmanifesting carriers,6 controls and 56 idiopathicPD.80% of LRRK2-PD and one unaffected carrier were positive. Exploratory mitochondrial genetic burden association also used a PPMI replication component.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 21 ], "verification": "verified", "verified_against": "abstract_metadata: Complete PubMed abstract and linked status fields examined; article body and supplements not examined.", "verified_on": "2026-10-03", "note": "Full genotyped cohort counts are not SAA sample sizes. Genetic associations with SAA do not establish direct toxicity, misfolded mediation of LRRK2 risk, or a selective survival response." }, { "id": "C22", "text": "Original retrospective clinicopathologic/genetic analysis included 3353 eligible donors from 11 brain banks. PD/PDD/DLB clinical diagnoses had 92.0% positive predictive value for Lewy pathology;33/745 neurologically normal controls had Lewy pathology. AD copathology occurred in 426/1064 Lewy-disease cases; GBA1 carriers had more extensive Lewy burden than noncarriers/LRRK2 carriers.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 22 ], "verification": "verified", "verified_against": "full_text_partial: Complete abstract plus full Methods and Results examined; Discussion and supplementary eTables not fully read. Related preprint 41929290 identity/status inspected and attached, not separately counted.", "verified_on": "2026-10-03", "note": "Pathological prevalence or burden is not direct misfolded-species causality. Incidental Lewy pathology does not prove protection or absence of prodromal disease. Misdiagnosed clinicalPD cases should not be recast as proven alpha-synuclein-independent idiopathicPD." }, { "id": "C23", "text": "An Australian G51D kindred showed young-onset parkinsonism and variable expression: proband motor onset 38 and cognitive symptoms 41, sisters onset 51 and 28, and a 27-year-old carrier with subtle thumb tremor. Proband autopsy showed diffuse Lewy pathology.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 23 ], "verification": "verified", "verified_against": "abstract_metadata: Complete PubMed abstract and linked status fields examined; article body and supplements not examined.", "verified_on": "2026-10-03", "note": "Independent kindred replication does not isolate the toxic conformer or supply human selective-aggregation rescue. Variable ages/features preclude an unconditional allele-to-fixed-trajectory prediction." }, { "id": "C24", "text": "UKBiobank screening of about 500000 people identified 30 SNCA copy-number events (6 duplications,6 deletions,18 complex events), many suspected mosaic. None had diagnosedPD at the reported follow-up; three had some prodromal features without meeting prodromal criteria. Seven of 18 complex events had blood cancer.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 24 ], "verification": "verified", "verified_against": "abstract_metadata: Complete PubMed abstract and linked status fields examined; article body and supplements not examined.", "verified_on": "2026-10-03", "note": "Blood mosaic gains are not established germline brain SNCA duplication and incomplete age/follow-up does not prove inherited dosage harmless. The data constrain indiscriminate penetrance claims, not all familial SNCA causality." }, { "id": "C25", "text": "Original case-control haplotype analysis found common SNCA haplotypes associated with Parkinson disease, extending locus relevance beyond rare Mendelian coding/copy-number families.", "carries_number": false, "load_bearing_for": [ "SC4" ], "source_ns": [ 25 ], "verification": "verified", "verified_against": "abstract_metadata: Complete PubMed abstract and linked status fields examined; article body and supplements not examined.", "verified_on": "2026-10-03", "note": "Locus association does not establish a causal allele, valid mediation instrument, toxic conformer, or selective change in dopaminergic survival. It cannot alone cross a causal perturbation threshold." }, { "id": "C26", "text": "Oligomer-promoting variants cause greater dopaminergic neuronal loss than fast fibril-forming variants. NeuN comparisons support actual loss; even weaker-promoter expression exceeded familial triplication levels, and unrelated HET-s aggregates were not similarly toxic.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 26 ], "verification": "verified", "verified_against": "full_text_partial: PubMed abstract/status plus selected primary Results/Discussion and design descriptions returned by web search at https://pmc.ncbi.nlm.nih.gov/articles/PMC3053976/ examined: variant controls, NeuN/TH comparison, lower-promoter expression still above familial triplication and HET-s aggregate control. Europe PMC failed500; PMC dataset supplied no XML URL and direct PMC met a browser challenge. Full Methods/supplements not audited.", "verified_on": "2026-10-03", "note": "Mutation changes can alter membrane/function properties as well as assembly; does not identify a universal native sporadic-PD toxic species." }, { "id": "C27", "text": "Prefibrillar variants associate with increased neuronal toxicity and behavioral defects across model systems.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 27 ], "verification": "verified", "verified_against": "abstract_metadata: PubMed primary abstract and linked-status metadata examined; no Methods/Results or complete-body/supplement examination claimed.", "verified_on": "2026-10-03", "note": "Biophysical convergence does not separate all normal-function changes; not spontaneous human dopamine-neuron loss." }, { "id": "C28", "text": "Dopaminergic apoptosis depends on endogenous dopamine and ROS; soluble alpha-syn/14-3-3 complexes are implicated, whereas cortical neurons show protection.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 28 ], "verification": "verified", "verified_against": "abstract_metadata: PubMed primary abstract and linked-status metadata examined; no Methods/Results or complete-body/supplement examination claimed.", "verified_on": "2026-10-03", "note": "Does not establish fibrils or inclusions as the harmful species, ordinary in vivo exposure, or sporadic progression mediation." }, { "id": "C29", "text": "Snca deletion protects against L-DOPA-induced death without reducing cytosolic dopamine; calcium/dopamine differences confer SN susceptibility.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 29 ], "verification": "verified", "verified_against": "full_text_partial: PubMed abstract/status and PMC dataset XML focused Methods/Results examined: native knockout/littermates, astrocyte-supported postnatal cultures, dopamine/calcium perturbation and TH/MAP2 survival counting. No complete-body/supplement audit.", "verified_on": "2026-10-03", "note": "Identifies alpha-syn-dependent vulnerability, not a particular misfolded toxic species or an exclusively protein-first process." }, { "id": "C30", "text": "Seeded pathology progresses with selective SNpc dopamine-neuron loss, reduced dopamine and motor deficits, while adjacent VTA is spared. PBS/monomer and Snca-null recipients lack the same pathology/DA-loss outcome; not all gross/open-field motor outcomes change.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 30 ], "verification": "verified", "verified_against": "full_text_partial: PubMed abstract/status and PMC dataset XML selected main Results examined: PBS/monomer controls, native Snca-null comparator, time/region pathology versus loss and motor dissociations. Formal methods are in supplements not audited. Partial Results reading, not complete-paper examination.", "verified_on": "2026-10-03", "note": "Does not establish spontaneous sporadic initiation, isolate one conformer or rule out indirect/glial mediators. Main-text loss estimates are TH-defined; complete supplemental stereological details not audited." }, { "id": "C31", "text": "PFFs recruit native alpha-syn into Lewy-like pathology with synaptic/electrical deficits and later neuronal death.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 31 ], "verification": "verified", "verified_against": "abstract_metadata: PubMed primary abstract and linked-status metadata examined; no Methods/Results or complete-body/supplement examination claimed.", "verified_on": "2026-10-03", "note": "Neuron death is not specifically human dopaminergic loss; forced initiation and indirect culture effects remain." }, { "id": "C32", "text": "Inclusion maturation coincides with organelle sequestration, mitochondrial/synaptic disruption and later death beyond early fibrillization. Snca-null cultures do not show PFF-associated death; glial TUNEL precedes later neuronal NeuN/TUNEL death.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 32 ], "verification": "verified", "verified_against": "full_text_partial: PubMed abstract/status and Europe PMC XML selected Results examined: stage-specific respiration/organelle assays and KO, glial-versus-neuronal death comparisons. Formal Methods refer to an SI Appendix not examined. No complete-body/supplement audit.", "verified_on": "2026-10-03", "note": "Temporal stages alone do not fully isolate causality; is not proof that every mature inclusion is protective or toxic in human PD. Earlier glial injury leaves non-cell-autonomous contribution possible." }, { "id": "C33", "text": "Incomplete aggregate degradation generates a distinct nonfibrillar fragment associated with mitochondrial damage, energetic stress and mitophagy.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 33 ], "verification": "verified", "verified_against": "abstract_metadata: PubMed primary abstract and linked-status metadata examined; no Methods/Results or complete-body/supplement examination claimed.", "verified_on": "2026-10-03", "note": "Cannot infer all injury is direct from localization; selective native conformer depletion and human degeneration mediation are not established in accessed abstract." }, { "id": "C34", "text": "Knockout resists dopamine-neuron degeneration; resistance tracks inability of MPTP to inhibit complex I rather than abnormal dopamine-transporter function.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 34 ], "verification": "verified", "verified_against": "abstract_metadata: PubMed primary abstract and linked-status metadata examined; no Methods/Results or complete-body/supplement examination claimed.", "verified_on": "2026-10-03", "note": "Deletion changes normal protein biology and toxin response; no isolated misfolded-species removal." }, { "id": "C35", "text": "Suppression precedes MHC-I induction, microglial/T-cell recruitment and later nigrostriatal neuronal loss; control hairpin/cerebellar exposure does not reproduce injury.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 35 ], "verification": "verified", "verified_against": "abstract_metadata: PubMed primary abstract and linked-status metadata examined; no Methods/Results or complete-body/supplement examination claimed.", "verified_on": "2026-10-03", "note": "Does not prove every suppression strategy is unsafe or exclude shRNA/dose effects; no exclusive misfolded gain-of-function instrument." }, { "id": "C36", "text": "Partial knockdown is tolerated at baseline and protects rotenone-exposed nigral neurons/terminals while attenuating motor deficits. Blinded counts co-label TH, MAP2 and nuclei; functional/neuritic protection accompanies counts.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 36 ], "verification": "verified", "verified_against": "full_text_partial: PubMed abstract/status and selected primary Methods/Results returned by web search at https://pmc.ncbi.nlm.nih.gov/articles/PMC4563670/ examined: paired-vector lesion comparisons and blinded stereology of co-labeled MAP2/TH/nuclei. Europe PMC failed500 and PMC dataset supplied no XML URL. No full-body/supplement audit.", "verified_on": "2026-10-03", "note": "Total protein reduction changes normal function and aggregation substrate simultaneously; does not selectively identify a misfolded toxic species. Count inclusion requires TH positivity, so it is not an independent Nissl-only rescue measure." }, { "id": "C37", "text": "Strong long-term knockdown shows no Nissl-defined neuron loss or significant motor dysfunction; TH declines with both vectors.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 37 ], "verification": "verified", "verified_against": "full_text_partial: PubMed abstract/status and PMC dataset XML focused Methods/Results examined: vector specificity/batches, Nissl/DAPI versus TH counting and long-term clinical/molecular outcomes. Figure1 comparison inset reuses 2015 data; new cohort measured here. No complete-body/supplement audit.", "verified_on": "2026-10-03", "note": "Tolerance in this delivery context does not prove universal safety or disease rescue. TH-positive count alone can conflate phenotype suppression with death." }, { "id": "C38", "text": "ASOs reduce pathology and preserve TH-positive counts; some pretreatment paradigms normalize dopamine. Transient post-seed treatment later preserves TH despite increased aggregate counts.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 38 ], "verification": "verified", "verified_against": "full_text_partial: Focused Europe PMC XML Methods/Results read: transient/sustained and pre/post-PFF ASOs, TH stereology, dopamine assays and PFF/animal dosing. No complete-body/supplement audit.", "verified_on": "2026-10-03", "note": "Examined survival estimates are TH-based, without separate pan-neuronal counts; total-protein lowering is not misfolded-specific. Behavioral improvement is a trend in the accessed mouse paradigm." }, { "id": "C39", "text": "Lag3 loss delays PFF-associated dopaminergic loss and biochemical/behavioral deficits. In vivo TH/Nissl stereology and dopamine/motor outcomes improve; cultured KO-to-re-expression rescue, PI/NeuN and calcium assays strengthen a model-specific uptake-to-injury dependency.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 39 ], "verification": "verified", "verified_against": "full_text_partial: PubMed abstract/status and PMC dataset XML focused Methods/Results examined: native receptor KO, neuronal rescue/PI/NeuN/calcium, PFF/monomer/PBS injections, TH/Nissl in vivo survival and motor outcomes; mouse strain has altered T-cell homeostasis. No full supplement audit.", "verified_on": "2026-10-03", "note": "Route dependence does not establish a mandatory extracellular mechanism for all PD or isolate intrinsic conformer toxicity; receptor expression/specificity is contested. Global Lag3 deletion also affects T-cell homeostasis; it is not a neuronal-specific knockout." }, { "id": "C40", "text": "No neuronal expression detected; inducible LAG3 does not increase human-culture seeding, knockout does not change A53T survival or slice pathology.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 40 ], "verification": "verified", "verified_against": "full_text_partial: New alpha-specific Europe PMC XML Methods/Results read: human-culture induction/seeding, A53T survival, PFF slices and animal/culture protocols. Expression sections were previously examined for tau; alpha intervention claims newly examined here. No complete supplement audit.", "verified_on": "2026-10-03", "note": "Different model/region from Mao nigrostriatal PFF experiment; not a direct refutation of all alpha-syn toxicity or all uptake routes." }, { "id": "C41", "text": "Aggregation-profile modulation restores dopamine release and preserves TH counts/gait; baseline nigral degeneration is NeuN-confirmed. Dense clusters/HMW signal decrease while dispersed small species increase.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 41 ], "verification": "verified", "verified_against": "full_text_partial: Focused Europe PMC XML Methods/Results read: model construction/null background, randomization/blinding, TH/NeuN baseline counting, anle138b timing, aggregate-profile and dopamine/TH outcomes. Selected reading; no complete-body/supplement audit.", "verified_on": "2026-10-03", "note": "Treatment rescue counts examined are TH-based; off-target aggregation-modulator effects and artificial substrate remain. Small species are not automatically the harmful oligomers of another assay." }, { "id": "C42", "text": "Reduced/absent SNCA alleles resist pS129 Lewy-like pathology.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 42 ], "verification": "verified", "verified_against": "abstract_metadata: PubMed primary abstract and linked-status metadata examined; no Methods/Results or complete-body/supplement examination claimed.", "verified_on": "2026-10-03", "note": "Accessed abstract does not show neuron-loss rescue; a seeding-resistant graft candidate is not established protection in human PD." }, { "id": "C43", "text": "Brain-amplified strains produce dose/strain-dependent death in triplication neurons, reversed by isogenic dosage normalization. Similar early seeding does not imply equal later toxicity.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2", "SC3", "SC4" ], "source_ns": [ 43 ], "verification": "verified", "verified_against": "full_text_partial: Focused Europe PMC XML Methods/Results read: brain amplification/controls, neuron differentiation, seed exposure, triplication/healthy-control comparison and isogenic SNCA correction. No complete-body/supplement audit.", "verified_on": "2026-10-03", "note": "Does not establish identical toxicity in normal-dose sporadic neurons; amplification may select conformers and gene-dose rescue is not misfolded-selective depletion." }, { "id": "C44", "text": "Equal-total-alpha-syn LA/SA patient fractions yield different time courses and similar later TH-defined nigrostriatal deficits. SA contains small amyloid assemblies, so its former noLB label does not mean no pathological alpha-syn.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 44 ], "verification": "verified", "verified_against": "full_text_partial: Focused Europe PMC XML Methods/Results read: fraction purification/characterization provenance, cohort allocation/injections, TH/Nissl methods and time-course degeneration. Earlier fraction characterization and 24-month observations explicitly reuse2020 report 32426502; supplements not comprehensively audited.", "verified_on": "2026-10-03", "note": "Not spontaneous human causality or alpha-syn-specific fraction toxicity: extract cofactors, sonication, untreated rather than matched extract controls and partial endpoint audit remain. Prior 24-month findings are reused." }, { "id": "C45", "text": "Parkin deficiency increases native aggregated/released/seeding-competent alpha-syn and synaptic/Ca2+ abnormalities, including dopamine-neuronal and astrocytic aggregates.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 45 ], "verification": "verified", "verified_against": "full_text_partial: Focused Europe PMC XML Methods/Results read: culture composition, native aggregates/seeding, synapse/calcium outcomes, differentiation and PARK2/SNCA CRISPRi assay design. No complete-body/supplement audit.", "verified_on": "2026-10-03", "note": "No alpha-syn-selective rescue establishes mediation or direct neuron death; PARK2 changes clearance/organellar biology upstream. Lewy-body absence cannot be equated with absence of soluble/pathological alpha-syn." }, { "id": "C46", "text": "Specific midbrain dopamine and other neuronal populations are lost, without association to region-level native alpha-syn expression.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 46 ], "verification": "verified", "verified_against": "abstract_metadata: PubMed primary abstract and linked-status metadata examined; no Methods/Results or complete-body/supplement examination claimed.", "verified_on": "2026-10-03", "note": "Regional expression is not single-cell exposure or genetic deletion; result does not prove alpha-syn-independent degeneration or ordinary spontaneous delivery." }, { "id": "C47", "text": "Lipophilic membrane interaction and bilayer insertion define toxic oligomer properties; targeted mutation reduces cellular toxicity.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 47 ], "verification": "verified", "verified_against": "abstract_metadata: PubMed primary abstract and linked-status metadata examined; no Methods/Results or complete-body/supplement examination claimed.", "verified_on": "2026-10-03", "note": "Membrane/toxicity mechanism is plausible but exposure, normal-function effects and human dopamine-cell specificity are unproven." }, { "id": "C48", "text": "Fibrils release toxic soluble oligomers; shorter fibrils cause greater immediate dysfunction consistent with more ends.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 48 ], "verification": "verified", "verified_against": "abstract_metadata: PubMed primary abstract and linked-status metadata examined; no Methods/Results or complete-body/supplement examination claimed.", "verified_on": "2026-10-03", "note": "Aggregate categories are kinetically interconverting; direct human dopamine-neuron loss or ordinary concentration is not established." }, { "id": "C49", "text": "Suppression produces marker-confirmed cell loss, striatal dopamine depletion and behavioral asymmetry; protein re-expression partially reverses injury.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 49 ], "verification": "verified", "verified_against": "full_text_partial: PubMed abstract/status plus selected primary Results/Discussion and design descriptions returned by web search at https://pmc.ncbi.nlm.nih.gov/articles/PMC2927065/ examined: two hairpins, three irrelevant controls, dose/efficacy and AADC/VMAT/GFP checks. Animal Methods/supplements not comprehensively audited; Europe PMC failed500 and PMC dataset supplied no XML URL.", "verified_on": "2026-10-03", "note": "Does not show misfolded accumulation removal is harmful, or invalidate all reduction therapies; vector/hairpin specificity, suppression level and rescue dose matter." }, { "id": "C50", "text": "Monomer protects against both catechols; fibrils improve DOPAL but not salsolinol viability, with potentially less-toxic DOPAL adduct formation.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 50 ], "verification": "verified", "verified_against": "abstract_metadata: PubMed primary abstract and linked-status metadata examined; no Methods/Results or complete-body/supplement examination claimed.", "verified_on": "2026-10-03", "note": "Not proof Lewy-body sequestration protects in human PD; response depends on toxin and assembly and may reflect chemical trapping rather than native intracellular storage." }, { "id": "C51", "text": "PASADENA randomized 316 early PD participants; neither prasinezumab dose met the global MDS-UPDRS primary endpoint, and dopamine-transporter imaging did not differ substantially from placebo.", "carries_number": true, "load_bearing_for": [ "SC3", "SC4" ], "source_ns": [ 51 ], "verification": "verified", "verified_against": "abstract_metadata: Primary PubMed abstract and metadata read.", "verified_on": "2026-10-03", "note": "Does not show disease modification or neuron survival; it tests extracellular antibody treatment after clinical diagnosis rather than selective removal of intracellular toxic conformers." }, { "id": "C52", "text": "Exploratory analyses of PASADENA baseline-defined subpopulations found a larger numerical motor-sign effect in groups expected to progress faster.", "carries_number": false, "load_bearing_for": [ "SC3", "SC4" ], "source_ns": [ 52 ], "verification": "verified", "verified_against": "full_text_partial: Primary abstract plus selected Methods, Results and/or Discussion paragraphs read in saved Europe PMC full text; tables, figures and supplements not fully audited.", "verified_on": "2026-10-03", "note": "These secondary analyses follow a failed primary endpoint; subgroup definitions were prespecified, but the effect interpretation remains exploratory and requires independent randomized confirmation." }, { "id": "C53", "text": "PASADENA open-label extension participants had slower motor-score deterioration than a weighted external PPMI comparator over four years.", "carries_number": false, "load_bearing_for": [ "SC3", "SC4" ], "source_ns": [ 53 ], "verification": "verified", "verified_against": "full_text_partial: Primary abstract plus selected Methods, Results and/or Discussion paragraphs read in saved Europe PMC full text; tables, figures and supplements not fully audited.", "verified_on": "2026-10-03", "note": "No concurrent placebo beyond the first year; selection, residual confounding, medication differences, examiner/placebo effects and cohort mismatch can explain some or all of the contrast; no direct neuronal survival or misfolded-species mediation." }, { "id": "C54", "text": "PADOVA randomized 586 early PD participants on stable symptomatic medication; the primary motor-event endpoint was not met (HR 0.84, 95% CI 0.69–1.01; p=0.066), with prespecified exploratory signals favoring further study.", "carries_number": true, "load_bearing_for": [ "SC3", "SC4" ], "source_ns": [ 54 ], "verification": "verified", "verified_against": "abstract_metadata: Primary PubMed abstract and metadata read.", "verified_on": "2026-10-03", "note": "A suggestive effect is not a positive primary trial or proof of neuroprotection/direct toxicity; the July 2026 erratum corrects the appendix but its detailed impact is unresolved because the corrected appendix was not examined." }, { "id": "C55", "text": "SPARK randomized 357 early PD participants; no cinpanemab dose improved clinical progression or DaT-SPECT versus placebo, and the trial was stopped for lack of efficacy.", "carries_number": true, "load_bearing_for": [ "SC3", "SC4" ], "source_ns": [ 55 ], "verification": "verified", "verified_against": "abstract_metadata: Primary PubMed abstract and metadata read.", "verified_on": "2026-10-03", "note": "No inference that every intracellular misfolded species was effectively neutralized; failure of this extracellular antibody does not establish lack of any alpha-synuclein contribution." }, { "id": "C56", "text": "SPARK biomarker analyses confirmed seeds in most of the baseline CSF subgroup, but neither clinical nor imaging/fluid biomarkers showed a cinpanemab treatment effect.", "carries_number": false, "load_bearing_for": [ "SC3", "SC4" ], "source_ns": [ 56 ], "verification": "verified", "verified_against": "abstract_metadata: Primary PubMed abstract and metadata read.", "verified_on": "2026-10-03", "note": "Baseline seeding positivity is disease classification, not toxic-species dependence or direct neuron killing; no substantial reduction of the measured seed signal was demonstrated." }, { "id": "C57", "text": "UB-312 phase 1 PD vaccination induced antibodies in serum and a subset of CSF samples; exploratory seed-amplification maximum fluorescence fell in one active dose group. Randomized groups did not differ statistically on clinical scales.", "carries_number": true, "load_bearing_for": [ "SC3", "SC4" ], "source_ns": [ 57 ], "verification": "verified", "verified_against": "full_text_partial: Primary abstract plus selected Methods, Results and/or Discussion paragraphs read in saved Europe PMC full text; tables, figures and supplements not fully audited.", "verified_on": "2026-10-03", "note": "The small safety/immunogenicity trial does not establish clinical benefit or neuronal preservation. Post-treatment antibody-positive subgroup contrasts are nonrandomized, and antibody effects on the amplification assay require separation from depletion of brain toxic species." }, { "id": "C58", "text": "PD01A dose-randomized phase 1 PD immunization and extensions showed a humoral response that could be reactivated with booster dosing and acceptable tolerability over follow-up.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 58 ], "verification": "verified", "verified_against": "abstract_metadata: Primary PubMed abstract and metadata read.", "verified_on": "2026-10-03", "note": "Dose comparison without a placebo efficacy contrast cannot demonstrate slowed degeneration; immunogenicity and inferred engagement do not isolate the proposed toxic mediator." }, { "id": "C59", "text": "PD03A placebo-controlled phase 1 PD vaccination generated anti-peptide and alpha-synuclein-specific antibodies with acceptable tolerability.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 59 ], "verification": "verified", "verified_against": "full_text_partial: Primary abstract plus selected Methods, Results and/or Discussion paragraphs read in saved Europe PMC full text; tables, figures and supplements not fully audited.", "verified_on": "2026-10-03", "note": "The safety study was not powered for clinical efficacy; no significant clinical-scale or striatal DAT-SPECT contrast, and symptomatic medication changes limit interpretation of clinical trends." }, { "id": "C60", "text": "Single-dose Lu AF82422 reduced plasma free alpha-synuclein and the CSF free-to-total ratio in the high-dose PD cohort, supporting central compartment engagement.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 60 ], "verification": "verified", "verified_against": "abstract_metadata: Primary PubMed abstract and metadata read.", "verified_on": "2026-10-03", "note": "Free/total ratio modulation does not demonstrate removal of neuron-intrinsic misfolded species, neuronal survival, or a clinical trajectory effect." }, { "id": "C61", "text": "MEDI1341 randomized phase 1 healthy and PD studies measured dose-dependent lowering of CSF free alpha-synuclein; the highest PD dose reduced the median CSF-free signal by 59.0% at Day85.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 61 ], "verification": "verified", "verified_against": "full_text_partial: Primary abstract plus selected Methods, Results and/or Discussion paragraphs read in saved Europe PMC full text; tables, figures and supplements not fully audited.", "verified_on": "2026-10-03", "note": "Target binding/sequestration lowers the free assay signal; it does not establish reduction of total pathogenic tissue burden or clinical disease modification. Read Methods/Results show no notable clinical treatment-group trends." }, { "id": "C62", "text": "Crosslink-stabilized assays of cinpanemab phase 1 samples directly detected dose- and time-dependent drug–alpha-synuclein complexes in human CSF.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 62 ], "verification": "verified", "verified_against": "abstract_metadata: Primary PubMed abstract and metadata read.", "verified_on": "2026-10-03", "note": "This corrects an absolute claim that CNS engagement was never measured, but does not demonstrate intracellular aggregate depletion or efficacy in the separate SPARK trial." }, { "id": "C63", "text": "Single-dose PRX002 in healthy participants produced dose-dependent reductions of free serum alpha-synuclein with favorable phase 1 tolerability.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 63 ], "verification": "verified", "verified_against": "abstract_metadata: Primary PubMed abstract and metadata read.", "verified_on": "2026-10-03", "note": "Peripheral serum binding in healthy participants gives no neuronal-survival or PD progression evidence; total signal increased after binding." }, { "id": "C64", "text": "Cinpanemab phase 1 healthy/PD study measured dose-proportional exposure and plasma complexes; CSF drug levels were a small fraction of serum levels.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 64 ], "verification": "verified", "verified_against": "full_text_partial: Primary abstract plus selected Methods, Results and/or Discussion paragraphs read in saved Europe PMC full text; tables, figures and supplements not fully audited.", "verified_on": "2026-10-03", "note": "The original phase 1 assay could not measure CSF complexes; this was subsequently resolved by the 2025 assay report from the same study, rather than representing two independent clinical experiments." }, { "id": "C65", "text": "Multiple-dose PRX002 in PD reduced free serum alpha-synuclein and produced dose-dependent CSF drug exposure with generally favorable phase 1 tolerability.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 65 ], "verification": "verified", "verified_against": "abstract_metadata: Primary PubMed abstract and metadata read.", "verified_on": "2026-10-03", "note": "CSF exposure was predicted to engage extracellular aggregates, rather than demonstrating their selective clearance or neuronal preservation." } ], "citation_ledger": [ { "n": 1, "citation": "Polymeropoulos MH, Lavedan C, Leroy E et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (New York, N.Y.). 1997. doi:10.1126/science.276.5321.2045", "tier": "A", "kind": "primary", "pmid": "9197268", "doi": "10.1126/science.276.5321.2045", "url": "https://pubmed.ncbi.nlm.nih.gov/9197268/", "status_flags": [ "none_found" ], "carries_claims": [ "C1" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "SNCA_A53T_ITALIAN_GREEK_KINDREDS_1997", "access_depth": "abstract_metadata", "access_note": "Complete PubMed abstract and linked status fields examined; article body and supplements not examined.", "independence_note": "Multiple reported kindreds support the coding-variant line; they are not four distinct mechanistic modalities." }, { "n": 2, "citation": "Zarranz JJ, Alegre J, Gómez-Esteban JC et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Annals of neurology. 2004. doi:10.1002/ana.10795", "tier": "A", "kind": "primary", "pmid": "14755719", "doi": "10.1002/ana.10795", "url": "https://pubmed.ncbi.nlm.nih.gov/14755719/", "status_flags": [ "none_found" ], "carries_claims": [ "C2" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "SNCA_E46K_SPANISH_KINDRED_2004", "access_depth": "abstract_metadata", "access_note": "Complete PubMed abstract and linked status fields examined; article body and supplements not examined.", "independence_note": "Independent coding kindred; one familial human line, not separate causal lines for genotype and pathology." }, { "n": 3, "citation": "Chartier-Harlin MC, Kachergus J, Roumier C et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet (London, England). 2004. doi:10.1016/S0140-6736(04)17103-1", "tier": "A", "kind": "primary", "pmid": "15451224", "doi": "10.1016/S0140-6736(04)17103-1", "url": "https://pubmed.ncbi.nlm.nih.gov/15451224/", "status_flags": [ "none_found" ], "carries_claims": [ "C3" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "SNCA_FRENCH_DUPLICATION_KINDRED_2004", "access_depth": "abstract_metadata", "access_note": "Complete PubMed abstract and linked status fields examined; article body and supplements not examined.", "independence_note": "French duplication family; Mutez 2011 appears to characterize a previously described French kindred, so conservatively grouped with this report pending full family identity verification." }, { "n": 4, "citation": "Ibáñez P, Bonnet AM, Débarges B et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet (London, England). 2004. doi:10.1016/S0140-6736(04)17104-3", "tier": "A", "kind": "primary", "pmid": "15451225", "doi": "10.1016/S0140-6736(04)17104-3", "url": "https://pubmed.ncbi.nlm.nih.gov/15451225/", "status_flags": [ "none_found" ], "carries_claims": [ "C4" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "SNCA_IBANEZ_DUPLICATION_FAMILIES_2004", "access_depth": "abstract_metadata", "access_note": "Complete PubMed abstract and linked status fields examined; article body and supplements not examined.", "independence_note": "Two duplication family observations strengthen the dosage line; replication alone does not create a new mechanistic class." }, { "n": 5, "citation": "Miller DW, Hague SM, Clarimon J et al. Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology. 2004. doi:10.1212/01.wnl.0000127517.33208.f4", "tier": "A", "kind": "primary", "pmid": "15159488", "doi": "10.1212/01.wnl.0000127517.33208.f4", "url": "https://pubmed.ncbi.nlm.nih.gov/15159488/", "status_flags": [ "none_found" ], "carries_claims": [ "C5" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "SNCA_IOWA_TRIPLICATION_KINDRED", "access_depth": "abstract_metadata", "access_note": "Complete PubMed abstract and linked status fields examined; article body and supplements not examined.", "independence_note": "Iowa kindred, shared with Zafar 2018 and foundational Singleton 2003; these reports constitute one dosage-family study group." }, { "n": 6, "citation": "Kiely AP, Asi YT, Kara E et al. α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta neuropathologica. 2013. doi:10.1007/s00401-013-1096-7", "tier": "A", "kind": "primary", "pmid": "23404372", "doi": "10.1007/s00401-013-1096-7", "url": "https://pubmed.ncbi.nlm.nih.gov/23404372/", "status_flags": [ "none_found" ], "carries_claims": [ "C6" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "SNCA_G51D_BRITISH_KINDRED_2013", "access_depth": "full_text_partial", "access_note": "Complete PubMed abstract plus full Materials and methods and Results, including genotype, clinical history, neuronal loss and neuronal/glial pathology, were examined; Discussion and supplements were not fully examined.", "independence_note": "One British G51D kindred; Australian 2026 is an independent kindred but remains replication of the coding-variant causal class." }, { "n": 7, "citation": "Proukakis C, Dudzik CG, Brier T et al. A novel α-synuclein missense mutation in Parkinson disease. Neurology. 2013. doi:10.1212/WNL.0b013e31828727ba", "tier": "A", "kind": "primary", "pmid": "23427326", "doi": "10.1212/WNL.0b013e31828727ba", "url": "https://pubmed.ncbi.nlm.nih.gov/23427326/", "status_flags": [ "none_found" ], "carries_claims": [ "C7" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "SNCA_H50Q_INDEX_CASE_2013", "access_depth": "abstract_metadata", "access_note": "Entire short PubMed abstract and identity/status metadata examined. Europe PMC fullTextXML request for PMC3653201 returned HTTP500; body was not examined.", "independence_note": "Index H50Q case; keep separate from the later population challenge but do not treat their directions as independent positive lines." }, { "n": 8, "citation": "Blauwendraat C, Kia DA, Pihlstrøm L et al. Insufficient evidence for pathogenicity of SNCA His50Gln (H50Q) in Parkinson's disease. Neurobiology of aging. 2018. doi:10.1016/j.neurobiolaging.2017.12.012", "tier": "A", "kind": "primary", "pmid": "29398121", "doi": "10.1016/j.neurobiolaging.2017.12.012", "url": "https://pubmed.ncbi.nlm.nih.gov/29398121/", "status_flags": [ "none_found" ], "carries_claims": [ "C8" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "SNCA_H50Q_POPULATION_REASSESSMENT_2018", "access_depth": "abstract_metadata", "access_note": "Complete PubMed abstract and linked status metadata examined. Europe PMC fullTextXML request for PMC5823280 returned HTTP500; body/supplements were not examined.", "independence_note": "Population reassessment supplies a different failure test than the original single-case nomination; not a separate positive causal line." }, { "n": 9, "citation": "Zafar F, Valappil RA, Kim S et al. Genetic fine-mapping of the Iowan SNCA gene triplication in a patient with Parkinson's disease. NPJ Parkinson's disease. 2018. doi:10.1038/s41531-018-0054-4", "tier": "A", "kind": "primary", "pmid": "29928688", "doi": "10.1038/s41531-018-0054-4", "url": "https://pubmed.ncbi.nlm.nih.gov/29928688/", "status_flags": [ "none_found" ], "carries_claims": [ "C9" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "SNCA_IOWA_TRIPLICATION_KINDRED", "access_depth": "full_text_partial", "access_note": "Complete abstract and full Results and Methods were examined, including clinical/autopsy findings, copy-number mapping and expression methods; Discussion and supplements not fully read. Human natural experiment is the counted component.", "independence_note": "Same Iowa kindred as Miller 2004; Lister mapping is a distinct comparator but does not convert one report into two independent causal modalities." }, { "n": 10, "citation": "Mutez E, Leprêtre F, Le Rhun E et al. SNCA locus duplication carriers: from genetics to Parkinson disease phenotypes. Human mutation. 2011. doi:10.1002/humu.21459", "tier": "A", "kind": "primary", "pmid": "21412942", "doi": "10.1002/humu.21459", "url": "https://pubmed.ncbi.nlm.nih.gov/21412942/", "status_flags": [ "none_found" ], "carries_claims": [ "C10" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "SNCA_FRENCH_DUPLICATION_KINDRED_2004", "access_depth": "abstract_metadata", "access_note": "Complete PubMed abstract and linked status fields examined; article body and supplements not examined.", "independence_note": "Reported as a previously described duplication kindred. Conservatively grouped with Chartier-Harlin 2004 French family rather than claiming an additional causal family; full family identity not independently resolved." }, { "n": 11, "citation": "Doherty KM, Silveira-Moriyama L, Parkkinen L et al. Parkin disease: a clinicopathologic entity? JAMA neurology. 2013. doi:10.1001/jamaneurol.2013.172", "tier": "A", "kind": "primary", "pmid": "23459986", "doi": "10.1001/jamaneurol.2013.172", "url": "https://pubmed.ncbi.nlm.nih.gov/23459986/", "status_flags": [ "none_found" ], "carries_claims": [ "C11" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "PRKN_DOHERTY_FIVE_CASE_AUTOPSY_2013", "access_depth": "abstract_metadata", "access_note": "Complete structured PubMed abstract and status metadata examined. Europe PMC fullTextXML request for PMC4202385 returned HTTP500; full Methods/Results not examined.", "independence_note": "Five original unrelated parkin cases, not the narrative commentary 23653422. Pathological observations remain one modality." }, { "n": 12, "citation": "Martí-Massó JF, Ruiz-Martínez J, Bolaño MJ et al. Neuropathology of Parkinson's disease with the R1441G mutation in LRRK2. Movement disorders : official journal of the Movement Disorder Society. 2009. doi:10.1002/mds.22677", "tier": "A", "kind": "primary", "pmid": "19735093", "doi": "10.1002/mds.22677", "url": "https://pubmed.ncbi.nlm.nih.gov/19735093/", "status_flags": [ "none_found" ], "carries_claims": [ "C12" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "LRRK2_R1441G_MARTIMASSO_SINGLE_AUTOPSY_2009", "access_depth": "abstract_metadata", "access_note": "Complete PubMed abstract and linked status fields examined; article body and supplements not examined.", "independence_note": "One original R1441G autopsy; do not multiply it with narrative summaries or differently phrased case reports." }, { "n": 13, "citation": "Shahmoradian SH, Lewis AJ, Genoud C et al. Lewy pathology in Parkinson's disease consists of crowded organelles and lipid membranes. Nature neuroscience. 2019. doi:10.1038/s41593-019-0423-2", "tier": "A", "kind": "primary", "pmid": "31235907", "doi": "10.1038/s41593-019-0423-2", "url": "https://pubmed.ncbi.nlm.nih.gov/31235907/", "status_flags": [ "none_found" ], "carries_claims": [ "C13" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "SHAHMORADIAN_LEWY_ULTRASTRUCTURE_2019", "access_depth": "abstract_metadata", "access_note": "Complete PubMed abstract and linked status fields examined; article body and supplements not examined.", "independence_note": "One ultrastructural human investigation with orthogonal measurements; multiple imaging resolutions are not multiple causal lines." }, { "n": 14, "citation": "Neumann J, Bras J, Deas E et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain : a journal of neurology. 2009. doi:10.1093/brain/awp044", "tier": "A", "kind": "primary", "pmid": "19286695", "doi": "10.1093/brain/awp044", "url": "https://pubmed.ncbi.nlm.nih.gov/19286695/", "status_flags": [ "none_found" ], "carries_claims": [ "C14" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "GBA_UK_NEUMANN_CLINICAL_AUTOPSY_2009", "access_depth": "abstract_metadata", "access_note": "Complete PubMed abstract and linked status fields examined; article body and supplements not examined.", "independence_note": "UK clinical/autopsy study. Overlap with Sidransky 2009 multicenter genetic sample is not resolved; do not treat the two as wholly independent GBA causal lines." }, { "n": 15, "citation": "Sidransky E, Nalls MA, Aasly JO et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. The New England journal of medicine. 2009. doi:10.1056/NEJMoa0901281", "tier": "A", "kind": "primary", "pmid": "19846850", "doi": "10.1056/NEJMoa0901281", "url": "https://pubmed.ncbi.nlm.nih.gov/19846850/", "status_flags": [ "none_found" ], "carries_claims": [ "C15" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "GBA_SIDRANSKY_MULTICENTER_CASECONTROL_2009", "access_depth": "abstract_metadata", "access_note": "Complete PubMed abstract and linked status fields examined; article body and supplements not examined.", "independence_note": "One original multinational association study;16 centers do not equal 16 independent mechanisms. Potential UK overlap remains explicitly unresolved." }, { "n": 16, "citation": "Mokretar K, Pease D, Taanman JW et al. Somatic copy number gains of α-synuclein (SNCA) in Parkinson's disease and multiple system atrophy brains. Brain : a journal of neurology. 2018. doi:10.1093/brain/awy157", "tier": "A", "kind": "primary", "pmid": "29917054", "doi": "10.1093/brain/awy157", "url": "https://pubmed.ncbi.nlm.nih.gov/29917054/", "status_flags": [ "none_found" ], "carries_claims": [ "C16" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "MOKRETAR_SNCA_SOMATIC_NIGRA_FISH_2018", "access_depth": "abstract_metadata", "access_note": "Complete PubMed abstract and linked status fields examined; article body and supplements not examined.", "independence_note": "One original blinded brain FISH investigation; separate probes validate measurement rather than add causal lines." }, { "n": 17, "citation": "Siderowf A, Concha-Marambio L, Lafontant DE et al. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study. The Lancet. Neurology. 2023. doi:10.1016/S1474-4422(23)00109-6", "tier": "A", "kind": "primary", "pmid": "37059509", "doi": "10.1016/S1474-4422(23)00109-6", "url": "https://pubmed.ncbi.nlm.nih.gov/37059509/", "status_flags": [ "none_found" ], "carries_claims": [ "C17" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "PPMI_CSF_SAA_PROGRAM", "access_depth": "abstract_metadata", "access_note": "Complete structured PubMed abstract and linked status fields examined. PMC10627170 fullTextXML request returned HTTP500; full protocol and supplements were not examined.", "independence_note": "PPMI cohort program shared with the 2025 kinetic analysis and the PPMI portion of 2026 LRRK2 analysis; these are overlapping reports, not independent human causal interventions." }, { "n": 18, "citation": "Jensen NM, Vitic Z, Antorini MR et al. Abundant non-inclusion α-synuclein pathology in Lewy body-negative LRRK2-mutant cases. Acta neuropathologica. 2025. doi:10.1007/s00401-025-02871-w", "tier": "A", "kind": "primary", "pmid": "40314782", "doi": "10.1007/s00401-025-02871-w", "url": "https://pubmed.ncbi.nlm.nih.gov/40314782/", "status_flags": [ "none_found" ], "carries_claims": [ "C18" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "JENSEN_UK_LRRK2_VARIANT_PLA_AUTOPSY_2025", "access_depth": "full_text_partial", "access_note": "Complete abstract, full Materials and methods and Results, and cohort Table 1 examined. Discussion/supplements not fully read; quantitative loss was not performed by authors.", "independence_note": "UK Parkinson/Oxford brain-bank cases differ from the Sydney cases in Jensen 2024, but both use the same PLA measurement class; replication is not a new causal modality." }, { "n": 19, "citation": "Jensen NM, Fu Y, Betzer C et al. MJF-14 proximity ligation assay detects early non-inclusion alpha-synuclein pathology with enhanced specificity and sensitivity. NPJ Parkinson's disease. 2024. doi:10.1038/s41531-024-00841-9", "tier": "A", "kind": "primary", "pmid": "39613827", "doi": "10.1038/s41531-024-00841-9", "url": "https://pubmed.ncbi.nlm.nih.gov/39613827/", "status_flags": [ "none_found" ], "carries_claims": [ "C19" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "JENSEN_SYDNEY_HUMAN_PLA_AUTOPSY_2024", "access_depth": "full_text_partial", "access_note": "Complete abstract plus human tissue/PLA Methods; DLB and PD human Results; and mouse specificity-control Results examined. Other cell-culture/neuronal validation and all supplements not fully read; counted only original human component.", "independence_note": "Original Sydney human series; different cases from UK2025, shared assay/systematic specificity constraints." }, { "n": 20, "citation": "Orrú CD, Vaughan DP, Vijiaratnam N et al. Diagnostic and prognostic value of α-synuclein seed amplification assay kinetic measures in Parkinson's disease: a longitudinal cohort study. The Lancet. Neurology. 2025. doi:10.1016/S1474-4422(25)00157-7", "tier": "A", "kind": "primary", "pmid": "40541208", "doi": "10.1016/S1474-4422(25)00157-7", "url": "https://pubmed.ncbi.nlm.nih.gov/40541208/", "status_flags": [ "none_found" ], "carries_claims": [ "C20" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "PPMI_CSF_SAA_PROGRAM", "access_depth": "abstract_metadata", "access_note": "Complete PubMed abstract and linked status fields examined; article body and supplements not examined.", "independence_note": "PPMI component overlaps Siderowf 2023; independent UK/Tuebingen replication supports prognostic confidence, not a new causal perturbation. Study-group ID conservatively marks the shared largest component." }, { "n": 21, "citation": "Lüth T, Gabbert C, Kleinz T et al. α-Synuclein Seeding Discriminates Between LRRK2 G2019S Variant Carriers with and Without Parkinson's Disease. Movement disorders : official journal of the Movement Disorder Society. 2026. doi:10.1002/mds.70553", "tier": "A", "kind": "primary", "pmid": "42806694", "doi": "10.1002/mds.70553", "url": "https://pubmed.ncbi.nlm.nih.gov/42806694/", "status_flags": [ "none_found" ], "carries_claims": [ "C21" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "NORWAY_LRRK2_SAA_PLUS_PPMI_PROGRAM_2026", "access_depth": "abstract_metadata", "access_note": "Complete PubMed abstract and linked status fields examined; article body and supplements not examined.", "independence_note": "Norwegian assay cohort is a distinct sample; PPMI355 idiopathicPD/118 LRRK2-PD genetic replication reuses the PPMI program and is not independent causal evidence." }, { "n": 22, "citation": "Wu LY, du Toit T, Georgiades T et al. Pathology and Genetics in a Global Cohort of Parkinsonian Disorders. JAMA neurology. 2026. doi:10.1001/jamaneurol.2026.1634", "tier": "A", "kind": "primary", "pmid": "42258190", "doi": "10.1001/jamaneurol.2026.1634", "url": "https://pubmed.ncbi.nlm.nih.gov/42258190/", "status_flags": [ "none_found" ], "carries_claims": [ "C22" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "MDGAP_GP2_MULTIBRAINBANK_AUTOPSY_2026", "access_depth": "full_text_partial", "access_note": "Complete abstract plus full Methods and Results examined; Discussion and supplementary eTables not fully read. Related preprint 41929290 identity/status inspected and attached, not separately counted.", "independence_note": "One pooled original MD-GAP/GP2 analysis;11 brain banks and 3353 reports are not independent causal modalities. Potential donor overlap with earlier brain-bank reports unresolved." }, { "n": 23, "citation": "Panegyres PK, Kwok JB, Junckerstorff R. Clinicopathological characterisation of the first Australian family with the p.G51D SNCA mutation. Parkinsonism & related disorders. 2026. doi:10.1016/j.parkreldis.2026.108955", "tier": "A", "kind": "primary", "pmid": "42660007", "doi": "10.1016/j.parkreldis.2026.108955", "url": "https://pubmed.ncbi.nlm.nih.gov/42660007/", "status_flags": [ "none_found" ], "carries_claims": [ "C23" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "SNCA_G51D_AUSTRALIAN_KINDRED_2026", "access_depth": "abstract_metadata", "access_note": "Complete PubMed abstract and linked status fields examined; article body and supplements not examined.", "independence_note": "Distinct Australian rather than British G51D kindred; strengthens coding-variant confidence, not an additional perturbation modality." }, { "n": 24, "citation": "Blauwendraat C, Makarious MB, Leonard HL et al. A population scale analysis of rare SNCA variation in the UK Biobank. Neurobiology of disease. 2021. doi:10.1016/j.nbd.2020.105182", "tier": "A", "kind": "primary", "pmid": "33307186", "doi": "10.1016/j.nbd.2020.105182", "url": "https://pubmed.ncbi.nlm.nih.gov/33307186/", "status_flags": [ "none_found" ], "carries_claims": [ "C24" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "UKBIOBANK_RARE_SNCA_COPYVARIANTS_2021", "access_depth": "abstract_metadata", "access_note": "Complete PubMed abstract and linked status fields examined; article body and supplements not examined.", "independence_note": "Independent population ascertainment counters disease-family selection; not a direct misfolded-species experiment." }, { "n": 25, "citation": "Farrer M, Maraganore DM, Lockhart P et al. alpha-Synuclein gene haplotypes are associated with Parkinson's disease. Human molecular genetics. 2001. doi:10.1093/hmg/10.17.1847", "tier": "A", "kind": "primary", "pmid": "11532993", "doi": "10.1093/hmg/10.17.1847", "url": "https://pubmed.ncbi.nlm.nih.gov/11532993/", "status_flags": [ "none_found" ], "carries_claims": [ "C25" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "SNCA_COMMON_HAPLOTYPES_CASECONTROL_2001", "access_depth": "abstract_metadata", "access_note": "Complete PubMed abstract and linked status fields examined; article body and supplements not examined.", "independence_note": "One original common-haplotype association study; distinct sampling scope from Mendelian families but association remains one nonperturbational class." }, { "n": 26, "citation": "Winner B et al. (2011). In vivo demonstration that alpha-synuclein oligomers are toxic. Proceedings of the National Academy of Sciences of the United States of America. DOI: 10.1073/pnas.1100976108.", "tier": "A", "kind": "primary", "pmid": "21325059", "doi": "10.1073/pnas.1100976108", "url": "https://pubmed.ncbi.nlm.nih.gov/21325059/", "status_flags": [ "none_found" ], "carries_claims": [ "C26" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "Winner2011_21325059", "access_depth": "full_text_partial", "access_note": "PubMed abstract/status plus selected primary Results/Discussion and design descriptions returned by web search at https://pmc.ncbi.nlm.nih.gov/articles/PMC3053976/ examined: variant controls, NeuN/TH comparison, lower-promoter expression still above familial triplication and HET-s aggregate control. Europe PMC failed500; PMC dataset supplied no XML URL and direct PMC met a browser challenge. Full Methods/supplements not audited.", "independence_note": "Winner/Masliah/Gage experimental program; variants within one program are linked tests, not independent causal lines." }, { "n": 27, "citation": "Karpinar DP et al. (2009). Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. The EMBO journal. DOI: 10.1038/emboj.2009.257.", "tier": "A", "kind": "primary", "pmid": "19745811", "doi": "10.1038/emboj.2009.257", "url": "https://pubmed.ncbi.nlm.nih.gov/19745811/", "status_flags": [ "none_found" ], "carries_claims": [ "C27" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "Karpinar2009_19745811", "access_depth": "abstract_metadata", "access_note": "PubMed primary abstract and linked-status metadata examined; no Methods/Results or complete-body/supplement examination claimed.", "independence_note": "Karpinar/Griesinger experimental series; orthogonal systems share the same engineered-variant assumption." }, { "n": 28, "citation": "Xu J et al. (2002). Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nature medicine. DOI: 10.1038/nm0602-600.", "tier": "A", "kind": "primary", "pmid": "12042811", "doi": "10.1038/nm0602-600", "url": "https://pubmed.ncbi.nlm.nih.gov/12042811/", "status_flags": [ "none_found" ], "carries_claims": [ "C28" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "Xu2002_12042811", "access_depth": "abstract_metadata", "access_note": "PubMed primary abstract and linked-status metadata examined; no Methods/Results or complete-body/supplement examination claimed.", "independence_note": "Xu/Yankner human-cell study; distinct platform from rodent PFF and suppression experiments." }, { "n": 29, "citation": "Mosharov EV et al. (2009). Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron. DOI: 10.1016/j.neuron.2009.01.033.", "tier": "A", "kind": "primary", "pmid": "19409267", "doi": "10.1016/j.neuron.2009.01.033", "url": "https://pubmed.ncbi.nlm.nih.gov/19409267/", "status_flags": [ "none_found" ], "carries_claims": [ "C29" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "Mosharov2009_19409267", "access_depth": "full_text_partial", "access_note": "PubMed abstract/status and PMC dataset XML focused Methods/Results examined: native knockout/littermates, astrocyte-supported postnatal cultures, dopamine/calcium perturbation and TH/MAP2 survival counting. No complete-body/supplement audit.", "independence_note": "Mosharov/Sulzer dopamine-homeostasis series; gene-level instrument fails differently from conformer assays." }, { "n": 30, "citation": "Luk KC et al. (2012). Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science (New York, N.Y.). DOI: 10.1126/science.1227157.", "tier": "A", "kind": "primary", "pmid": "23161999", "doi": "10.1126/science.1227157", "url": "https://pubmed.ncbi.nlm.nih.gov/23161999/", "status_flags": [ "none_found" ], "carries_claims": [ "C30" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "Luk2012_23161999", "access_depth": "full_text_partial", "access_note": "PubMed abstract/status and PMC dataset XML selected main Results examined: PBS/monomer controls, native Snca-null comparator, time/region pathology versus loss and motor dissociations. Formal methods are in supplements not audited. Partial Results reading, not complete-paper examination.", "independence_note": "Luk/Lee Penn PFF program; overlaps investigators/platform with Volpicelli-Daley and Mao material." }, { "n": 31, "citation": "Volpicelli-Daley LA et al. (2011). Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron. DOI: 10.1016/j.neuron.2011.08.033.", "tier": "A", "kind": "primary", "pmid": "21982369", "doi": "10.1016/j.neuron.2011.08.033", "url": "https://pubmed.ncbi.nlm.nih.gov/21982369/", "status_flags": [ "none_found" ], "carries_claims": [ "C31" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "Volpicelli-Daley2011_21982369", "access_depth": "abstract_metadata", "access_note": "PubMed primary abstract and linked-status metadata examined; no Methods/Results or complete-body/supplement examination claimed.", "independence_note": "Volpicelli-Daley/Lee Penn PFF series; linked model assumptions with Luk2012." }, { "n": 32, "citation": "Mahul-Mellier AL et al. (2020). The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America. DOI: 10.1073/pnas.1913904117.", "tier": "A", "kind": "primary", "pmid": "32075919", "doi": "10.1073/pnas.1913904117", "url": "https://pubmed.ncbi.nlm.nih.gov/32075919/", "status_flags": [ "none_found" ], "carries_claims": [ "C32" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "Mahul-Mellier2020_32075919", "access_depth": "full_text_partial", "access_note": "PubMed abstract/status and Europe PMC XML selected Results examined: stage-specific respiration/organelle assays and KO, glial-versus-neuronal death comparisons. Formal Methods refer to an SI Appendix not examined. No complete-body/supplement audit.", "independence_note": "Mahul-Mellier/Lashuel inclusion-biogenesis program; distinct structural/omics platform but shares PFF initiation." }, { "n": 33, "citation": "Grassi D et al. (2018). Identification of a highly neurotoxic α-synuclein species inducing mitochondrial damage and mitophagy in Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America. DOI: 10.1073/pnas.1713849115.", "tier": "A", "kind": "primary", "pmid": "29487216", "doi": "10.1073/pnas.1713849115", "url": "https://pubmed.ncbi.nlm.nih.gov/29487216/", "status_flags": [ "none_found" ], "carries_claims": [ "C33" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "Grassi2018_29487216", "access_depth": "abstract_metadata", "access_note": "PubMed primary abstract and linked-status metadata examined; no Methods/Results or complete-body/supplement examination claimed.", "independence_note": "Grassi/Lasmezas mitochondrial-conformer program; clearance failure can generate toxic species rather than exclude direct toxicity." }, { "n": 34, "citation": "Dauer W et al. (2002). Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. Proceedings of the National Academy of Sciences of the United States of America. DOI: 10.1073/pnas.172514599.", "tier": "A", "kind": "primary", "pmid": "12376616", "doi": "10.1073/pnas.172514599", "url": "https://pubmed.ncbi.nlm.nih.gov/12376616/", "status_flags": [ "none_found" ], "carries_claims": [ "C34" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "Dauer2002_12376616", "access_depth": "abstract_metadata", "access_note": "PubMed primary abstract and linked-status metadata examined; no Methods/Results or complete-body/supplement examination claimed.", "independence_note": "Dauer/Sulzer genetic-toxin study; shared investigators with Mosharov but different in vivo toxin mechanism." }, { "n": 35, "citation": "Benskey MJ et al. (2018). Silencing Alpha Synuclein in Mature Nigral Neurons Results in Rapid Neuroinflammation and Subsequent Toxicity. Frontiers in molecular neuroscience. DOI: 10.3389/fnmol.2018.00036.", "tier": "A", "kind": "primary", "pmid": "29497361", "doi": "10.3389/fnmol.2018.00036", "url": "https://pubmed.ncbi.nlm.nih.gov/29497361/", "status_flags": [ "none_found" ], "carries_claims": [ "C35" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "Benskey2018_29497361", "access_depth": "abstract_metadata", "access_note": "PubMed primary abstract and linked-status metadata examined; no Methods/Results or complete-body/supplement examination claimed.", "independence_note": "Benskey/Manfredsson suppression program; mechanistic extension of loss-of-function toxicity, not independent replication of every RNAi method." }, { "n": 36, "citation": "Zharikov AD et al. (2015). shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model. The Journal of clinical investigation. DOI: 10.1172/JCI64502.", "tier": "A", "kind": "primary", "pmid": "26075822", "doi": "10.1172/JCI64502", "url": "https://pubmed.ncbi.nlm.nih.gov/26075822/", "status_flags": [ "none_found" ], "carries_claims": [ "C36" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "Zharikov2015_26075822", "access_depth": "full_text_partial", "access_note": "PubMed abstract/status and selected primary Methods/Results returned by web search at https://pmc.ncbi.nlm.nih.gov/articles/PMC4563670/ examined: paired-vector lesion comparisons and blinded stereology of co-labeled MAP2/TH/nuclei. Europe PMC failed500 and PMC dataset supplied no XML URL. No full-body/supplement audit.", "independence_note": "Zharikov/Greenamyre adult RNAi program; distinct toxin line, correlated vector assumptions with its long-term follow-up." }, { "n": 37, "citation": "Zharikov A et al. (2019). Long-term RNAi knockdown of α-synuclein in the adult rat substantia nigra without neurodegeneration. Neurobiology of disease. DOI: 10.1016/j.nbd.2019.01.004.", "tier": "A", "kind": "primary", "pmid": "30658149", "doi": "10.1016/j.nbd.2019.01.004", "url": "https://pubmed.ncbi.nlm.nih.gov/30658149/", "status_flags": [ "none_found" ], "carries_claims": [ "C37" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "Zharikov2019_30658149", "access_depth": "full_text_partial", "access_note": "PubMed abstract/status and PMC dataset XML focused Methods/Results examined: vector specificity/batches, Nissl/DAPI versus TH counting and long-term clinical/molecular outcomes. Figure1 comparison inset reuses 2015 data; new cohort measured here. No complete-body/supplement audit.", "independence_note": "Zharikov/Greenamyre RNAi program; separate age/duration experiment from 2015, shared delivery/lab failure modes." }, { "n": 38, "citation": "Cole TA et al. (2021). α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease. JCI insight. DOI: 10.1172/jci.insight.135633.", "tier": "A", "kind": "primary", "pmid": "33682798", "doi": "10.1172/jci.insight.135633", "url": "https://pubmed.ncbi.nlm.nih.gov/33682798/", "status_flags": [ "none_found" ], "carries_claims": [ "C38" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "Cole2021_33682798", "access_depth": "full_text_partial", "access_note": "Focused Europe PMC XML Methods/Results read: transient/sustained and pre/post-PFF ASOs, TH stereology, dopamine assays and PFF/animal dosing. No complete-body/supplement audit.", "independence_note": "Cole/Ionis/Greenamyre ASO program; multiple paradigms are one linked therapeutic program, not independent human causal lines." }, { "n": 39, "citation": "Mao X et al. (2016). Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science (New York, N.Y.). DOI: 10.1126/science.aah3374.", "tier": "A", "kind": "primary", "pmid": "27708076", "doi": "10.1126/science.aah3374", "url": "https://pubmed.ncbi.nlm.nih.gov/27708076/", "status_flags": [ "none_found" ], "carries_claims": [ "C39" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "Mao2016_27708076", "access_depth": "full_text_partial", "access_note": "PubMed abstract/status and PMC dataset XML focused Methods/Results examined: native receptor KO, neuronal rescue/PI/NeuN/calcium, PFF/monomer/PBS injections, TH/Nissl in vivo survival and motor outcomes; mouse strain has altered T-cell homeostasis. No full supplement audit.", "independence_note": "Mao/Dawson LAG3 program; one receptor program with linked molecular and outcome assays." }, { "n": 40, "citation": "Emmenegger M et al. (2021). LAG3 is not expressed in human and murine neurons and does not modulate α-synucleinopathies. EMBO molecular medicine. DOI: 10.15252/emmm.202114745.", "tier": "A", "kind": "primary", "pmid": "34309222", "doi": "10.15252/emmm.202114745", "url": "https://pubmed.ncbi.nlm.nih.gov/34309222/", "status_flags": [ "none_found" ], "carries_claims": [ "C40" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "Emmenegger2021_34309222", "access_depth": "full_text_partial", "access_note": "New alpha-specific Europe PMC XML Methods/Results read: human-culture induction/seeding, A53T survival, PFF slices and animal/culture protocols. Expression sections were previously examined for tau; alpha intervention claims newly examined here. No complete supplement audit.", "independence_note": "Emmenegger/Aguzzi/Jucker/Polymenidou independent receptor-specificity program; some transcript datasets reused, alpha-specific intervention sections newly read for this review." }, { "n": 41, "citation": "Wegrzynowicz M et al. (2019). Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model. Acta neuropathologica. DOI: 10.1007/s00401-019-02023-x.", "tier": "A", "kind": "primary", "pmid": "31165254", "doi": "10.1007/s00401-019-02023-x", "url": "https://pubmed.ncbi.nlm.nih.gov/31165254/", "status_flags": [ "none_found" ], "carries_claims": [ "C41" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "Wegrzynowicz2019_31165254", "access_depth": "full_text_partial", "access_note": "Focused Europe PMC XML Methods/Results read: model construction/null background, randomization/blinding, TH/NeuN baseline counting, anle138b timing, aggregate-profile and dopamine/TH outcomes. Selected reading; no complete-body/supplement audit.", "independence_note": "Wegrzynowicz/Spillantini/Giese MI2 program; imaging, pathology and drug rescue are linked program components." }, { "n": 42, "citation": "Chen Y et al. (2019). Engineering synucleinopathy-resistant human dopaminergic neurons by CRISPR-mediated deletion of the SNCA gene. The European journal of neuroscience. DOI: 10.1111/ejn.14286.", "tier": "A", "kind": "primary", "pmid": "30472757", "doi": "10.1111/ejn.14286", "url": "https://pubmed.ncbi.nlm.nih.gov/30472757/", "status_flags": [ "none_found" ], "carries_claims": [ "C42" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "Chen2019_30472757", "access_depth": "abstract_metadata", "access_note": "PubMed primary abstract and linked-status metadata examined; no Methods/Results or complete-body/supplement examination claimed.", "independence_note": "Chen/Morgan stem-cell editing program; native human gene instrument tests substrate requirement but not clinical progression." }, { "n": 43, "citation": "Tanudjojo B et al. (2021). Phenotypic manifestation of α-synuclein strains derived from Parkinson's disease and multiple system atrophy in human dopaminergic neurons. Nature communications. DOI: 10.1038/s41467-021-23682-z.", "tier": "A", "kind": "primary", "pmid": "34155194", "doi": "10.1038/s41467-021-23682-z", "url": "https://pubmed.ncbi.nlm.nih.gov/34155194/", "status_flags": [ "none_found" ], "carries_claims": [ "C43" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "Tanudjojo2021_34155194", "access_depth": "full_text_partial", "access_note": "Focused Europe PMC XML Methods/Results read: brain amplification/controls, neuron differentiation, seed exposure, triplication/healthy-control comparison and isogenic SNCA correction. No complete-body/supplement audit.", "independence_note": "Tanudjojo/Ryten/Kunath/Melki human-strain program; three clones from one triplication background are not three independent patients; isogenic lines originate in prior work." }, { "n": 44, "citation": "Kinet R et al. (2025). Differential pathological dynamics triggered by distinct Parkinson patient-derived α-synuclein extracts in nonhuman primates. Science advances. DOI: 10.1126/sciadv.adu6050.", "tier": "A", "kind": "primary", "pmid": "40531987", "doi": "10.1126/sciadv.adu6050", "url": "https://pubmed.ncbi.nlm.nih.gov/40531987/", "status_flags": [ "none_found" ], "carries_claims": [ "C44" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "Kinet2025_40531987", "access_depth": "full_text_partial", "access_note": "Focused Europe PMC XML Methods/Results read: fraction purification/characterization provenance, cohort allocation/injections, TH/Nissl methods and time-course degeneration. Earlier fraction characterization and 24-month observations explicitly reuse2020 report 32426502; supplements not comprehensively audited.", "independence_note": "Bezard/Dehay patient-fraction primate program; explicitly reuses fraction characterization and 24-month observations from Bourdenx 2020 PMID 32426502/DOI 10.1126/sciadv.aaz9165. Earlier 6/12-month/proteomic analysis extends that program rather than constituting an independent replication." }, { "n": 45, "citation": "Schmidt SI et al. (2025). Formation of seeding-competent α-synuclein aggregates in parkin-deficient iPSC-derived human neurons. NPJ Parkinson's disease. DOI: 10.1038/s41531-025-01038-4.", "tier": "A", "kind": "primary", "pmid": "40541955", "doi": "10.1038/s41531-025-01038-4", "url": "https://pubmed.ncbi.nlm.nih.gov/40541955/", "status_flags": [ "none_found" ], "carries_claims": [ "C45" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "Schmidt2025_40541955", "access_depth": "full_text_partial", "access_note": "Focused Europe PMC XML Methods/Results read: culture composition, native aggregates/seeding, synapse/calcium outcomes, differentiation and PARK2/SNCA CRISPRi assay design. No complete-body/supplement audit.", "independence_note": "2025 PARK2 isogenic culture program; clones/differentiations test one upstream genetic context, not population generalization." }, { "n": 46, "citation": "Kuan WL et al. (2023). Selective neurodegeneration generated by intravenous α-synuclein pre-formed fibril administration is not associated with endogenous α-synuclein levels in the rat brain. Brain pathology (Zurich, Switzerland). DOI: 10.1111/bpa.13128.", "tier": "A", "kind": "primary", "pmid": "36321260", "doi": "10.1111/bpa.13128", "url": "https://pubmed.ncbi.nlm.nih.gov/36321260/", "status_flags": [ "none_found" ], "carries_claims": [ "C46" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "Kuan2023_36321260", "access_depth": "abstract_metadata", "access_note": "PubMed primary abstract and linked-status metadata examined; no Methods/Results or complete-body/supplement examination claimed.", "independence_note": "Independent systemic-delivery rat program; route/dose assumptions differ from intracerebral PFF studies." }, { "n": 47, "citation": "Fusco G et al. (2017). Structural basis of membrane disruption and cellular toxicity by α-synuclein oligomers. Science (New York, N.Y.). DOI: 10.1126/science.aan6160.", "tier": "A", "kind": "primary", "pmid": "29242346", "doi": "10.1126/science.aan6160", "url": "https://pubmed.ncbi.nlm.nih.gov/29242346/", "status_flags": [ "none_found" ], "carries_claims": [ "C47" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "Fusco2017_29242346", "access_depth": "abstract_metadata", "access_note": "PubMed primary abstract and linked-status metadata examined; no Methods/Results or complete-body/supplement examination claimed.", "independence_note": "Fusco/Vendruscolo/Dobson structural program; orthogonal physical mechanism but shared recombinant preparation failure mode." }, { "n": 48, "citation": "Cascella R et al. (2021). The release of toxic oligomers from α-synuclein fibrils induces dysfunction in neuronal cells. Nature communications. DOI: 10.1038/s41467-021-21937-3.", "tier": "A", "kind": "primary", "pmid": "33753734", "doi": "10.1038/s41467-021-21937-3", "url": "https://pubmed.ncbi.nlm.nih.gov/33753734/", "status_flags": [ "none_found" ], "carries_claims": [ "C48" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "Cascella2021_33753734", "access_depth": "abstract_metadata", "access_note": "PubMed primary abstract and linked-status metadata examined; no Methods/Results or complete-body/supplement examination claimed.", "independence_note": "Cascella/Cecchi recombinant species-release program; distinct kinetics assay with shared artificial-assembly assumptions." }, { "n": 49, "citation": "Gorbatyuk OS et al. (2010). In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration. Molecular therapy : the journal of the American Society of Gene Therapy. DOI: 10.1038/mt.2010.115.", "tier": "A", "kind": "primary", "pmid": "20551914", "doi": "10.1038/mt.2010.115", "url": "https://pubmed.ncbi.nlm.nih.gov/20551914/", "status_flags": [ "none_found" ], "carries_claims": [ "C49" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "Gorbatyuk2010_20551914", "access_depth": "full_text_partial", "access_note": "PubMed abstract/status plus selected primary Results/Discussion and design descriptions returned by web search at https://pmc.ncbi.nlm.nih.gov/articles/PMC2927065/ examined: two hairpins, three irrelevant controls, dose/efficacy and AADC/VMAT/GFP checks. Animal Methods/supplements not comprehensively audited; Europe PMC failed500 and PMC dataset supplied no XML URL.", "independence_note": "Gorbatyuk suppression/rescue program; native-function causal counterpoint, with delivery failure modes shared by other AAV RNAi studies." }, { "n": 50, "citation": "Carmo-Gonçalves P et al. (2020). In Vitro Protective Action of Monomeric and Fibrillar α-Synuclein on Neuronal Cells Exposed to the Dopaminergic Toxins Salsolinol and DOPAL. ACS chemical neuroscience. DOI: 10.1021/acschemneuro.0c00527.", "tier": "A", "kind": "primary", "pmid": "33080132", "doi": "10.1021/acschemneuro.0c00527", "url": "https://pubmed.ncbi.nlm.nih.gov/33080132/", "status_flags": [ "none_found" ], "carries_claims": [ "C50" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "Carmo-Gonçalves2020_33080132", "access_depth": "abstract_metadata", "access_note": "PubMed primary abstract and linked-status metadata examined; no Methods/Results or complete-body/supplement examination claimed.", "independence_note": "Independent catechol-protection primary culture assay; tests a different failure mode from pathological seeding." }, { "n": 51, "citation": "Pagano G et al. Trial of Prasinezumab in Early-Stage Parkinson's Disease. The New England journal of medicine. 2022. DOI: 10.1056/NEJMoa2202867; PMID: 35921451.", "tier": "A", "kind": "rct", "pmid": "35921451", "doi": "10.1056/NEJMoa2202867", "url": "https://pubmed.ncbi.nlm.nih.gov/35921451/", "status_flags": [ "none_found" ], "carries_claims": [ "C51" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "NCT03100149", "access_depth": "abstract_metadata", "access_note": "Primary PubMed abstract and metadata read.", "independence_note": "Clinical alpha-synuclein immunotherapy; cohort and modality shared failures retained." }, { "n": 52, "citation": "Pagano G et al. Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease. Nature medicine. 2024. DOI: 10.1038/s41591-024-02886-y; PMID: 38622249.", "tier": "A", "kind": "primary", "pmid": "38622249", "doi": "10.1038/s41591-024-02886-y", "url": "https://pubmed.ncbi.nlm.nih.gov/38622249/", "status_flags": [ "none_found" ], "carries_claims": [ "C52" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "NCT03100149", "access_depth": "full_text_partial", "access_note": "Primary abstract plus selected Methods, Results and/or Discussion paragraphs read in saved Europe PMC full text; tables, figures and supplements not fully audited.", "independence_note": "Clinical alpha-synuclein immunotherapy; cohort and modality shared failures retained." }, { "n": 53, "citation": "Pagano G et al. Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial. Nature medicine. 2024. DOI: 10.1038/s41591-024-03270-6; PMID: 39379705.", "tier": "A", "kind": "rct", "pmid": "39379705", "doi": "10.1038/s41591-024-03270-6", "url": "https://pubmed.ncbi.nlm.nih.gov/39379705/", "status_flags": [ "none_found" ], "carries_claims": [ "C53" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "NCT03100149", "access_depth": "full_text_partial", "access_note": "Primary abstract plus selected Methods, Results and/or Discussion paragraphs read in saved Europe PMC full text; tables, figures and supplements not fully audited.", "independence_note": "Clinical alpha-synuclein immunotherapy; cohort and modality shared failures retained." }, { "n": 54, "citation": "Nikolcheva T et al. Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study. Lancet (London, England). 2026. DOI: 10.1016/S0140-6736(26)00865-2; PMID: 42208564.", "tier": "A", "kind": "rct", "pmid": "42208564", "doi": "10.1016/S0140-6736(26)00865-2", "url": "https://pubmed.ncbi.nlm.nih.gov/42208564/", "status_flags": [ "erratum: PMID 42392102; DOI 10.1016/S0140-6736(26)01301-2; appendix corrected as of 2026-07-02; correction body read; corrected appendix not examined, detailed scientific impact unresolved." ], "carries_claims": [ "C54" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "NCT04777331", "access_depth": "abstract_metadata", "access_note": "Primary PubMed abstract and metadata read.", "independence_note": "Clinical alpha-synuclein immunotherapy; cohort and modality shared failures retained." }, { "n": 55, "citation": "Lang AE et al. Trial of Cinpanemab in Early Parkinson's Disease. The New England journal of medicine. 2022. DOI: 10.1056/NEJMoa2203395; PMID: 35921450.", "tier": "A", "kind": "rct", "pmid": "35921450", "doi": "10.1056/NEJMoa2203395", "url": "https://pubmed.ncbi.nlm.nih.gov/35921450/", "status_flags": [ "none_found" ], "carries_claims": [ "C55" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "NCT03318523", "access_depth": "abstract_metadata", "access_note": "Primary PubMed abstract and metadata read.", "independence_note": "Clinical alpha-synuclein immunotherapy; cohort and modality shared failures retained." }, { "n": 56, "citation": "Hutchison RM et al. Cinpanemab in Early Parkinson Disease: Evaluation of Biomarker Results From the Phase 2 SPARK Clinical Trial. Neurology. 2024. DOI: 10.1212/WNL.0000000000209137; PMID: 38315945.", "tier": "A", "kind": "rct", "pmid": "38315945", "doi": "10.1212/WNL.0000000000209137", "url": "https://pubmed.ncbi.nlm.nih.gov/38315945/", "status_flags": [ "none_found" ], "carries_claims": [ "C56" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "NCT03318523", "access_depth": "abstract_metadata", "access_note": "Primary PubMed abstract and metadata read.", "independence_note": "Clinical alpha-synuclein immunotherapy; cohort and modality shared failures retained." }, { "n": 57, "citation": "Eijsvogel P et al. Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial. Nature medicine. 2024. DOI: 10.1038/s41591-024-03101-8; PMID: 38902546.", "tier": "A", "kind": "rct", "pmid": "38902546", "doi": "10.1038/s41591-024-03101-8", "url": "https://pubmed.ncbi.nlm.nih.gov/38902546/", "status_flags": [ "none_found" ], "carries_claims": [ "C57" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "NCT04075318", "access_depth": "full_text_partial", "access_note": "Primary abstract plus selected Methods, Results and/or Discussion paragraphs read in saved Europe PMC full text; tables, figures and supplements not fully audited.", "independence_note": "Clinical alpha-synuclein immunotherapy; cohort and modality shared failures retained." }, { "n": 58, "citation": "Volc D et al. Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial. The Lancet. Neurology. 2020. DOI: 10.1016/S1474-4422(20)30136-8; PMID: 32562684.", "tier": "A", "kind": "rct", "pmid": "32562684", "doi": "10.1016/S1474-4422(20)30136-8", "url": "https://pubmed.ncbi.nlm.nih.gov/32562684/", "status_flags": [ "none_found" ], "carries_claims": [ "C58" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "PD01A-program:EudraCT2011-002650-31/2013-001774-20/2014-002489-54/2015-004854-16", "access_depth": "abstract_metadata", "access_note": "Primary PubMed abstract and metadata read.", "independence_note": "Clinical alpha-synuclein immunotherapy; cohort and modality shared failures retained." }, { "n": 59, "citation": "Poewe W et al. Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson's Disease: A Randomized, Placebo-Controlled, Phase 1 Study. Journal of Parkinson's disease. 2021. DOI: 10.3233/JPD-212594; PMID: 34092654.", "tier": "A", "kind": "rct", "pmid": "34092654", "doi": "10.3233/JPD-212594", "url": "https://pubmed.ncbi.nlm.nih.gov/34092654/", "status_flags": [ "none_found" ], "carries_claims": [ "C59" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "PD03A-EudraCT2014-000568-16", "access_depth": "full_text_partial", "access_note": "Primary abstract plus selected Methods, Results and/or Discussion paragraphs read in saved Europe PMC full text; tables, figures and supplements not fully audited.", "independence_note": "Clinical alpha-synuclein immunotherapy; cohort and modality shared failures retained." }, { "n": 60, "citation": "Buur L et al. Randomized Phase I Trial of the α-Synuclein Antibody Lu AF82422. Movement disorders : official journal of the Movement Disorder Society. 2024. DOI: 10.1002/mds.29784; PMID: 38494847.", "tier": "A", "kind": "rct", "pmid": "38494847", "doi": "10.1002/mds.29784", "url": "https://pubmed.ncbi.nlm.nih.gov/38494847/", "status_flags": [ "none_found" ], "carries_claims": [ "C60" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "NCT03611569", "access_depth": "abstract_metadata", "access_note": "Primary PubMed abstract and metadata read.", "independence_note": "Clinical alpha-synuclein immunotherapy; cohort and modality shared failures retained." }, { "n": 61, "citation": "Shering C et al. Phase 1, randomized trials of MEDI1341: cerebrospinal fluid free α-synuclein lowered by >50. Brain communications. 2025. DOI: 10.1093/braincomms/fcaf304; PMID: 40936651.", "tier": "A", "kind": "primary", "pmid": "40936651", "doi": "10.1093/braincomms/fcaf304", "url": "https://pubmed.ncbi.nlm.nih.gov/40936651/", "status_flags": [ "none_found" ], "carries_claims": [ "C61" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "NCT03272165+NCT04449484", "access_depth": "full_text_partial", "access_note": "Primary abstract plus selected Methods, Results and/or Discussion paragraphs read in saved Europe PMC full text; tables, figures and supplements not fully audited.", "independence_note": "Clinical alpha-synuclein immunotherapy; cohort and modality shared failures retained." }, { "n": 62, "citation": "Liu Y et al. Quantification of cinpanemab (BIIB054) binding to α-synuclein in cerebrospinal fluid of phase 1 single ascending dose samples. The Journal of pharmacology and experimental therapeutics. 2025. DOI: 10.1124/jpet.124.002199; PMID: 39892989.", "tier": "A", "kind": "primary", "pmid": "39892989", "doi": "10.1124/jpet.124.002199", "url": "https://pubmed.ncbi.nlm.nih.gov/39892989/", "status_flags": [ "none_found" ], "carries_claims": [ "C62" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "NCT02459886", "access_depth": "abstract_metadata", "access_note": "Primary PubMed abstract and metadata read.", "independence_note": "Clinical alpha-synuclein immunotherapy; cohort and modality shared failures retained." }, { "n": 63, "citation": "Schenk DB et al. First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers. Movement disorders : official journal of the Movement Disorder Society. 2017. DOI: 10.1002/mds.26878; PMID: 27886407.", "tier": "A", "kind": "rct", "pmid": "27886407", "doi": "10.1002/mds.26878", "url": "https://pubmed.ncbi.nlm.nih.gov/27886407/", "status_flags": [ "none_found" ], "carries_claims": [ "C63" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "NCT02095171", "access_depth": "abstract_metadata", "access_note": "Primary PubMed abstract and metadata read.", "independence_note": "Clinical alpha-synuclein immunotherapy; cohort and modality shared failures retained." }, { "n": 64, "citation": "Brys M et al. Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054. Movement disorders : official journal of the Movement Disorder Society. 2019. DOI: 10.1002/mds.27738; PMID: 31211448.", "tier": "A", "kind": "rct", "pmid": "31211448", "doi": "10.1002/mds.27738", "url": "https://pubmed.ncbi.nlm.nih.gov/31211448/", "status_flags": [ "none_found" ], "carries_claims": [ "C64" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "NCT02459886", "access_depth": "full_text_partial", "access_note": "Primary abstract plus selected Methods, Results and/or Discussion paragraphs read in saved Europe PMC full text; tables, figures and supplements not fully audited.", "independence_note": "Clinical alpha-synuclein immunotherapy; cohort and modality shared failures retained." }, { "n": 65, "citation": "Jankovic J et al. Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial. JAMA neurology. 2018. DOI: 10.1001/jamaneurol.2018.1487; PMID: 29913017.", "tier": "A", "kind": "rct", "pmid": "29913017", "doi": "10.1001/jamaneurol.2018.1487", "url": "https://pubmed.ncbi.nlm.nih.gov/29913017/", "status_flags": [ "none_found" ], "carries_claims": [ "C65" ], "opened": true, "opened_on": "2026-10-03", "status_checked_on": "2026-10-03", "study_id": "NCT02157714", "access_depth": "abstract_metadata", "access_note": "Primary PubMed abstract and metadata read.", "independence_note": "Clinical alpha-synuclein immunotherapy; cohort and modality shared failures retained." } ], "independence_basis": { "required": true, "lines": [ { "label": "Familial SNCA coding-change natural experiments", "sources": [ 1, 2, 6, 23 ], "excludes_error": "Disease-linked coding changes in different pedigrees are not explained by one shared neighboring-gene multiplication or wild-type dosage alteration." }, { "label": "Wild-type SNCA dosage natural experiments", "sources": [ 3, 4, 5, 9 ], "excludes_error": "Confirmed copy-number and expression gains with disease cannot be attributed to one mutation-specific abnormal sequence or sequence-call artifact; boundaries/co-duplicated genes remain recorded." } ], "shared_failure_mode_checked": true, "note": "Required because SC1 is Ζ, although overall SC4 is Γ. Sequence and wild-type dosage perturbations have different causal-assignment errors; repeated Iowa/French family reports do not add lines. Human causal gene biology is supported, but no independent misfolded-species mediation lines are claimed." }, "falsification_audit": [ { "pattern": "Blocking the proposed mechanism does not alter onset/progression in vivo", "triggered": false, "evidence": "[51], [55], [54] are null on primary clinical outcomes; none demonstrates complete effective removal of the proposed intracellular toxic mediator. Do not apply a second downgrade for the same unproven-blockade boundary." }, { "pattern": "Pathology still initiates in its absence", "triggered": false, "evidence": "[11], [18] challenge a universal Lewy-inclusion requirement. Lewy negativity is not absence of every misfolded species, and the supplied claim does not assert necessity." }, { "pattern": "The claimed temporal order is not reproducible", "triggered": false, "evidence": "Postmortem burden/survivor bias cannot fix initiation timing; prodromal seeding precedes diagnosis in some cohorts but does not prove a uniform molecular sequence." }, { "pattern": "Alternative models explain the same findings more parsimoniously", "triggered": false, "evidence": "Several shared findings favor vulnerability/heterogeneity; no formal discriminating model-selection study establishes the full nominal false." }, { "pattern": "Subtype heterogeneity shows the mechanism is non-general but the hypothesis is framed as general", "triggered": false, "evidence": "Subtype observations restrict a universal claim but do not establish absence of a direct toxic contribution in ordinary sporadic PD. The limitation is scored once through SC4, without adding an unsupported falsification downgrade." } ], "study_grouping": { "groups": [ { "id": "PASADENA", "sources": [ 51, 52, 53 ], "relationship": "One randomized trial plus exploratory subgroup and external-comparator extension reports." }, { "id": "SPARK", "sources": [ 55, 56 ], "relationship": "One trial; biomarker report is not an independent efficacy study." }, { "id": "Cinpanemab-phase1", "sources": [ 64, 62 ], "relationship": "One phase 1 cohort; later CSF-binding analysis supersedes the original assay limitation." }, { "id": "Iowa-SNCA-triplication", "sources": [ 5, 9 ], "relationship": "Expression and expanded molecular characterization of the same underlying family; no duplicated natural-experiment line." }, { "id": "French-SNCA-duplication", "sources": [ 3, 10 ], "relationship": "Family/cohort relationship noted; exact participant overlap not fully resolved, so not counted as additional independence." } ], "causal_independence_count": null, "note": "Report count is not study count or causal-line count. PPMI SAA/cohort and connected laboratory platforms may share participants or measurements; exact overlap is not globally audited." }, "consensus_validation": { "completed": true, "local_date": "2026-10-09", "checked_utc": "2026-10-10T02:58:18.768457+00:00", "provider": "Consensus", "provider_mode": "Consensus browser Pro plus connector search/fetch, reconciled with original primary PubMed abstracts", "queries": [ "alpha synuclein Parkinson disease causal necessity sufficiency immunotherapy randomized trial prasinezumab cinpanemab SNCA human genetic mutations", "Through 3 October 2026, critically evaluate whether misfolded alpha-synuclein directly causes dopamine-neuron loss in typical sporadic Parkinson disease. Distinguish familial SNCA genetic causality, animal/model neurotoxicity and seeding, selective toxic-species removal, human causal necessity, and target-engaged clinical outcomes. Compare primary PASADENA, SPARK and PADOVA trials and exploratory follow-ups without counting the same trial twice; identify strongest supportive and contradictory primary evidence with PMID/DOI." ], "raw_paths": [ "consensus-search.json", "11f55a96e0375e878f4a8a3d81c1d753.json", "b9ecf5e8143857e1b22371bd3a0b9e40.json", "d53bdce6518e5c39a09f52220c475381.json", "browser-thread.json", "consensus-browser-response.md" ], "primary_comparisons": [ { "pmid": "35921451", "doi": "10.1056/NEJMoa2202867", "title": "Trial of Prasinezumab in Early-Stage Parkinson's Disease.", "access_depth": "abstract_metadata", "original_artifact": "primary.xml.records.json", "claim_checked": "PASADENA primary global progression and imaging outcomes did not improve meaningfully versus placebo.", "reconciliation": "Matches existing E51/[51]. Antibody exposure is not selective intracellular toxic-conformer depletion; a negative trial does not falsify every alpha-synuclein mechanism.", "verification": "verified", "source_url": "https://pubmed.ncbi.nlm.nih.gov/35921451/", "status_notices": [ { "type": "CommentIn", "pmid": "35921458", "note": "" }, { "type": "CommentIn", "pmid": "36151474", "note": "" }, { "type": "CommentIn", "pmid": "36404558", "note": "" }, { "type": "CommentIn", "pmid": "36519627", "note": "" } ] }, { "pmid": "35921450", "doi": "10.1056/NEJMoa2203395", "title": "Trial of Cinpanemab in Early Parkinson's Disease.", "access_depth": "abstract_metadata", "original_artifact": "primary.xml.records.json", "claim_checked": "SPARK found no clinical or DaT-SPECT benefit and stopped for lack of efficacy.", "reconciliation": "Matches E55/[55]. Distinct trial from PASADENA; no positive clinical causal threshold established.", "verification": "verified", "source_url": "https://pubmed.ncbi.nlm.nih.gov/35921450/", "status_notices": [] }, { "pmid": "39379705", "doi": "10.1038/s41591-024-03270-6", "title": "Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial.", "access_depth": "abstract_metadata", "original_artifact": "primary.xml.records.json", "claim_checked": "The PASADENA extension reported slower motor progression against an external observational comparator.", "reconciliation": "Matches E53/[53]. Exploratory open-label comparison, not concurrent-placebo replication. Same NCT03100149 family as E51; no additional independent randomized causal line.", "verification": "verified", "source_url": "https://pubmed.ncbi.nlm.nih.gov/39379705/", "status_notices": [] } ], "grade_changed": false, "prior_level": "Γ", "new_level": "Γ", "prior_confidence": "Moderate", "new_confidence": "Moderate", "review_type": "Retrospective consistency check with prior score visible; not independent blinded adjudication", "conclusion": "Hold the original SC1 Ζ / SC2 Γ / SC3 Γ / SC4 Γ and scope-matched overall Γ. These three rediscovered primary reports were already included and their Results agree with the original appraisals. No added source or independent causal line is credited.", "addendum_path": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\alpha-synuclein\\consensus-addendum.md", "thread_url": "https://consensus.app/search/alpha-synuclein-parkinson-causality/HQ86Wa25Rl6VsUDvHSlliw/", "additional_original_source_receipts": [], "primary_comparison_count": 3, "status": "completed_retrospective_original_source_reconciliation", "score_before": { "hsef_level": "Γ", "hsef_descriptor": "Mechanistically plausible, partial system support", "confidence": "Moderate", "confidence_rationale": "The mechanistic capability is supported across approaches and clinical primary results are verified against retrieved primary abstracts. Toxic-species assignment, physiology/exposure dependence, reused cohorts, partial full-text access and unresolved corrected-appendix details limit confidence in the full human scope; this is an evidence/access band, not a probability that α-synuclein is harmless.", "rests_on_non_peer_reviewed_work": false, "rationale": "Scope-matched preregistration yields SC4 Γ for the full human direct-toxicity/PD-loss claim; SC1 Ζ for familial SNCA biology is preserved separately. The examined causal work establishes more than association, but does not yet isolate the specified endogenous human toxic mediator and survival dependency. Null trials are not treated as complete mechanistic refutations." }, "score_after": { "hsef_level": "Γ", "hsef_descriptor": "Mechanistically plausible, partial system support", "confidence": "Moderate", "confidence_rationale": "The mechanistic capability is supported across approaches and clinical primary results are verified against retrieved primary abstracts. Toxic-species assignment, physiology/exposure dependence, reused cohorts, partial full-text access and unresolved corrected-appendix details limit confidence in the full human scope; this is an evidence/access band, not a probability that α-synuclein is harmless.", "rests_on_non_peer_reviewed_work": false, "rationale": "Scope-matched preregistration yields SC4 Γ for the full human direct-toxicity/PD-loss claim; SC1 Ζ for familial SNCA biology is preserved separately. The examined causal work establishes more than association, but does not yet isolate the specified endogenous human toxic mediator and survival dependency. Null trials are not treated as complete mechanistic refutations." }, "raw_receipts": [ { "path": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\alpha-synuclein\\consensus-search.json", "sha256": "f2a3bf445075eed53e5165157202f45e4e5bdc3185da0fb5f5029eb6cbf8039b" }, { "path": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\alpha-synuclein\\11f55a96e0375e878f4a8a3d81c1d753.json", "sha256": "e1bb5e2223c084e0f7d41eebd65f500f3f52ea9155687000ba186dbf93099e62" }, { "path": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\alpha-synuclein\\b9ecf5e8143857e1b22371bd3a0b9e40.json", "sha256": "086df925bcb53f8cb629fa44a536ccd6cf72713f7b409e4445c1bd538f922718" }, { "path": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\alpha-synuclein\\d53bdce6518e5c39a09f52220c475381.json", "sha256": "0657a80fd8f8ca746d5d94623816231b2d2c71839d77e00c112e721f4f49fc5e" }, { "path": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\alpha-synuclein\\browser-thread.json", "sha256": "38fab59f1c297426c45b42bce2a4c4a7c50cda0adebfe6d2d5ef2575421ae660" }, { "path": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\alpha-synuclein\\consensus-browser-response.md", "sha256": "bdf6584451acaf3846b30826b7e14c825c213e18c3f715f8ca476d23b602f989" } ], "manifest_source": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\alpha-synuclein\\consensus-validation.json", "literature_cutoff_preserved": true, "independent_blinded_audit": false } }